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ABSTRACT OF DISSERTATION

COFILIN NAVIGATES CELLULAR CYTOSKELETON
AND INVASION RESPONSESTO TGF-β
TOWARDS PROSTATE CANCER METASTASIS
Cofilin’s activity to nucleate actin filament assembly, is regulated by phosphorylation
at a single site on the amino terminus, Serine 3. Phosphorylation at this site abolishes the
ability of ADF/cofilin to bind to F-actin and inhibits its severing function. This work
characterizes the ability of dephosphorylated cofilin (mutation at Serine 3 site) to
navigate prostate cancer actin cytoskeleton and metastatic properties in response to TGFβ. TGF-β increased Lim Domain Kinase 2 (LIMK-2) activity leading to cofilin
phosphorylation and decrease actin filament severing in wild type cofilin (WTCFL) PC-3
cells. Constitutively active cofilin in Serine 3 cofilin mutants (S3ACFL) promoted
prostate cancer cell filopodia formation, actin severing and directed TGF-β mediated
migration and invasion. Co-culture of prostate cancer cells with prostate cancer
associated fibroblasts induced cell invasion in WTCFL and S3ACFL cells. Active cofilin
further enhanced the invasive response, even in the presence of a TGF-β-neutralizing
antibody, implicating the contribution of the microenvironment. Active cofilin led to a
significant increase in prostate cancer cell metastatic potential in vivo and cofilin
correlated with metastasis in a mouse model of prostate tumor progression. In human
prostate cancer, cofilin expression was significantly higher in metastasis compared to the
primary tumors. Cofilin thus emerges as a regulator of the actin cytoskeleton remodeling
capable of coordinating the cellular responses to TGF-β towards prostate cancer
metastasis. Understanding how cancer cells interprete TGF-β signals from the
microenvironment, is critical for defining the mechanism via which TGF-β function is
switched from a growth suppressor to a metastasis promoter. Here we show that in
prostate cancer, TGF-β action is directed by active cofilin enabling actin cytoskeleton
changes and metastatic behavior. The significant association of cofilin with prostate
cancer metastatic progression supports its predictive and targeting value in metastasis.
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.... to life “A la Vida”. And to all of us who live in love with life. Because science
would not be possible without a real passion for life and all its wonders.
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CHAPTER I

INTRODUCTION

Normal Prostate Gland Anatomy and Function

The prostate gland is an endocrine organ, located in the male pelvis, above the anus,
bellow the urethra and it is composed of glandular and fibromuscular tissue (Figure 1.1)
(Seisen T. et al.; 2012). The glandular cells are known to secrete the prostate specific
antigen PSA which have been used for many years for the screening and early detection
of prostate cancer. The prostate gland is essential for the process of fertilization, it is
responsible for the secretion of protein rich seminal fluids and proteases like the prostate
specific antigen (PSA) that nourishes and protect the sperm (Leissner & Tisell, et al.;
1979). These fluids are delivered into the urethra via prostate gland contractions where
they are expelled with sperm as semen during the process of ejaculation.
The prostate gland, develops from the endodermal urogenital sinus (UGS), which is
derived from the caudal terminus of the hindgut. Embryonic connective tissue known as
urogenital sinus mesenchyme (UGM) surrounds the embryonic connective tissue. (Cooke
1991). The growth and development of the prostate gland is dependent on androgens.
Androgens are mainly produced by the testes although a small amount of androgens are
known to be produced by the adrenal gland (Yadav N. et al. 2012). Testosterone is the
most predominant circulating androgen; in the prostate testosterone is converted to
dihydrotestosterone (DHT) by the enzyme 5α-reductase. Before sexual differentiation of
the UGS, UGM expresses androgen receptors (AR) in both sexes and thus acquires the
1

capacity to undergo masculine development (Cooke et al. 1991). In response to fetal
testicular androgens, epithelial buds are going to emerge from the wall of the UGS, grow
into the surrounding UGM, and form the lobar subdivisions of the prostate into dorsallateral, ventral, and anterior prostate (Price, 1963, Sugimura et al. 1986 , Kinbara and
Cunha 1995, Marker et al. 2003).
The androgenic effects on prostate development are mediated via androgen receptors
(AR). The androgen receptor not only plays a critical role in the normal development of
the prostate but in the process of prostate cancer development (Hodgson et al., 2012).
This transcription factor regulates the expression of genes that are responsible for the
modulation of epithelial cell growth, proliferation, survival, and differentiation (Cunha et
al., 2004, Heinlein & Chang, et al. 2002). Upon steroid binding the AR suffers a
conformational change which result in the dissociation of cytoplasmic chaperones
revealing the nuclear localization signal. The steroid bound receptor then translocates to
the nucleus, where it binds to DNA and interacts with transcriptional coregulators
regulating the expression of targeted genes (Koochekpour, 2010). The AR is known to be
expressed at some level in the majority of primary prostate cancers (Peter E. Lonergan,
Donal J Tindal 2011). Studies have established a relationship between the AR expression
levels in primary and metastatic progression to advanced castration resistant prostate
cancer (Hodgson et al., 2012).

2

Figure 1.1 The Anatomy of The Prostate. The prostate, gland is located between the
male bladder and the penis, in front of the rectum. The urethra runs through the center of
the prostate, from the bladder to the penis, allowing urine flow out of the body. The
prostate secretes fluid that nourishes and protects sperm. During ejaculation, the prostate
transports this fluid into the urethra, were is expelled with sperm as semen.
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Figure 1.1 The Anatomy of the Prostate
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Prostate Cancer Development and Progression
Prostate cancer or adenocarcinoma of the prostate is defined as a tumor growing in the
prostate gland (Figure 1.2). It is the most common form of cancer diagnosed in North
America (According to the American Cancer Society). The American Cancer Society has
estimated a number of 238,590 new cases of prostate cancer for 2013. It is also the
second leading cause of male cancer related deaths in the United States and unfortunately
29,720 of these patients will die from the disease as a result of metastatic spread to the
bone.
The tissue heterogeneity that characterizes prostate tumors has challenged the
development of reliable biomarkers for prediction and prognosis of the disease. Today,
there is a real need for the development of novel prostate cancer biomarkers that will
translate in better methods for screening, therapeutic approaches and implementing
prevention strategies. Identification of patients at ‘high risk’ for the development of
metastatic prostate cancer will allow for the selection of those patients that will benefit
from aggressive interventions to prevent progression and delay bone metastasis
(Logothetis et al, 2013).
The main risk factor for prostate cancer is age. About 5-10% of prostate cancers can be
attributed to gene defects, meaning that males with family history are more at risk of
developing prostate cancer themselves. Although several genes have been identified to be
involved in prostate cancer, the BRCA1 and BRCA2 genes are associated with having a
two to five times higher risk (Agalliu, 2009, Castro and Eeles, 2012, Dumitrescu, 2012).
A third risk factor for the development of prostate cancer is race; being African American
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males at higher risk of developing prostate cancer than White or Hispanic males
(Crawford 2003, Browley, 2012).
Prostate cancer progresses from prostatic intraepithelial neoplasia into metastatic and
androgen independent carcinoma (Figure 1.2). The bone is the most common metastatic
site of prostate cancer with 90% of patients with advanced prostate cancer developing
skeletal metastasis. The normal prostate gland is encapsulated by two layers of epithelial
cells known as the basal and luminal cell layers. As prostate cancer progresses, some
cancer cells with genetic predisposition and promotion by environmental stimuli, become
more aggressive, begin to degrade the surrounding double layer of epithelial cells and
escape into the stroma, triggering a series of molecular events known as the metastatic
cascade. The next step for this specific set of malignant cells is to directly invade the
surrounding tissue, or disseminate via lymphatic system allowing the spreading of cancer
cells, to those organs situated near the prostate such as the neurovascular bundle, penis,
seminal vesicles, bladder and rectum. The intravasation of cancer cells into the lymphatic
system result in the systemic spread of cancer cells to distant organs, including the bones,
lung, and liver.

Oncogenes and Tumor Suppressors in Prostate Cancer
Among the molecular pathways known to be altered in cancer oncogene activation and
tumor-suppressor suppression are the most common events triggering the initiation and
progression of most types of cancers, however a relatively small number have been found
to be implicated in prostate cancer. Some of the genes found to be altered in prostate
cancer are the oncogene Myc and the product of TMPRSS2:ETS gene fusions which are
6

often elevated throughout the course of disease progression. In addition, the
PI3K/AKT/mTOR pathway is commonly activated in prostate cancer due to the loss of
tumor-suppressor PTEN, while RB activity and/or expression loss have being found to
promote castration resistant prostate cancer.
PI3K activity plays a critical role in the regulation of cell growth and apoptosis. It is
known that about 40% of primary prostate cancers and 70% of metastatic prostate
cancers present gene alterations involving the PI3K/AKT pathway such as the loss of the
PTEN (phosphatase and tensin homolog), encoding a lipid phosphatase that negatively
regulates AKT activation (El Sheikh et al., 2008). Studies involving homozygous deletion
of PTEN in mouse models show that the loss of PTEN is sufficient to induce metastatic
tumors (Wan et al., 2003). However recent data have shown that PTEN deletions in
mouse knockout models are not sufficient to support progression into metastatic prostate
cancer, and suggested the involvement of additional molecular mechanisms supporting
metastatic spread including the AKT PI3K and TGF-β signaling (Bjerke et al. 2013).

7

Figure 1.2 Prostate Cancer Progression. Prostate cancer progresses from prostatic
epithelial neoplasia into metastatic and androgen dependent carcinoma. As prostate
cancer progresses, some cancer cells with genetic predisposition and promotion by
environmental stimuli, become more aggressive, begin to degrade the surrounding double
layer of epithelial cells and escape into the stroma.
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Figure modified from: Barron D A, and Rowley D R Endocr Relat Cancer 2012; 19:R187-R204

Figure 1.2 Prostate Cancer Progression
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Current Therapeutic Strategies For Prostate Cancer
Among the available prostate cancer therapies endorsed by the clinical practice;
surveillance, radical prostatectomy and external-beam radiotherapy are offered to men
with clinically localized prostate cancer (Thompson et al., 2007, Heidenreich, 2011).
Radical prostatectomy and radiation therapy are the most commonly used treatments for
organ confined tumors with a 10 year survival rate of 60%. However several side effects
including sexual, urinary and bowel dysfunction can affect the patient quality of life. The
only treatment conferring improved survival to patients with advanced metastatic prostate
cancer is androgen ablation therapy. The apoptotic response to androgen ablation is the
underlying mechanism driving tumor regression and therapeutic benefit in prostate cancer
patients (McKenzie and Kyprianou, 2006). The majority of prostate tumors recur
however emerging as castration-resistant, due to prostate cancer cells developing
resistance to androgen-ablation induced apoptosis.
Evolution from androgen dependent to androgen- independent prostate cancer
(currently known as castration-resistant prostate cancer) is the result of a complex
interplay of signaling pathways becoming dysfunctional, triggered by an aberrant AR
signaling (Lonergan and Tindal 2011). Several mechanisms have been proposed to lead
AR mediated castration resistance such as: 1) AR amplification/overexpression; 2) gain
of function; 3) intracrine androgen production 4) overexpression of AR cofactors; 5)
ligand independent AR activation by cytokines and growth factors; 6) constitutive active
messenger ribonucleic acids (mRNA) splice variants of AR. Molecular studies involving
immunohistochemical profiling of AR on tumor tissue samples from castration resistant
patients have shown that AR is not only highly expressed, but also transcriptionally
10

active (Ruizeveld de Winter et al., 1994, Taplin et al., 1995, Holzbeierleinet al., 2004 ).
In a similar way, studies in xenograft models also showed an increased in the expression
of AR and restoration of its activity in those tumors that relapsed after castration
(Gregory et al., 1998, Chen et al., 2004). These findings, together with studies involving
RNA interference confirm that AR was still required for growth in castration resistant
prostate cancer (CRPC). The high levels of androgens in samples from castration
resistant prostate cancer patients (Mohler et al., 2004, Titus et al., 2005), and compelling
evidence showing that tumors had increased expression of androgen synthesis enzymes,
(Stanbrough et al., 2006, Montgomery et al., 2008), implicate a castration resistance
mechanism, via which tumor cells are responsible for androgen synthesis, leading to the
reactivation of AR transcriptional activity and prostate cancer growth and progression.

Metastasis and The Tumor Microenvironment

The process of cancer metastasis is facilitated by interactions between cancer cells and
the tumor microenvironment (Fang and Declerck, 2013 Jezierska-Drutel, 2013, Astekar
et al., 2013). These interactions are mediated by growth factors secreted not only by
cancer cells but from additional components of the tumor microenvironment such as
immune cells, endothelial cells and fibroblasts (Figure 1.3) (Dutsch-Wicherek and
Kazmierczak, 2013). The contribution of growth factor secretions by different cell types
present in the tumor microenvironment enables the optimal conditions for the growth and
proliferation of cancer cells. For example, it is known that in breast cancer, parathyroid
hormone-related protein and interleukin (IL)-11, produced by cancer cells, activate
osteoclasts by the receptor activator of nuclear factor-κB (RANK)-RANK ligand
11

(RANKL) (Morgan et al., 2004). The activated osteoclasts are responsible for the
induction of bone-derived factors release. The molecular mechanisms responsible for
prostate cancer bone metastasis are not fully understood. However recent studies have
shown that the co - culture of LNCaP cells with mouse stromal MC3T3-E1 cells result in
the induction of osteoblastic differentiation of MC3T3-E1 cells. Furthermore, it have
been shown that LNCaP cells and BMP-4 can cooperatively induce the production of
growth factors, such as fibroblast growth factor (FGF)-2 and epidermal growth factor
(EGF) in MC3T3-E1 cells, promoting proliferation of LNCaP cells (Nishimori et al.,
2012). These stromal cancer cell interactions were found to not only favor the survival of
prostate cancer cells, but also induce the differentiation of bone stromal cells in the bone
microenvironment, facilitating the osteoblastic metastasis of prostate cancer (Nishimori et
al., 2012). These compelling findings implicate a direct contribution of the bone
microenvironment in facilitating the colonization of prostate cancer cells into the bone. In
an attempt to explain this organ specific pattern of metastatic spread not only observed in
prostate cancer but among different types of cancers, the “seed and soil” theory was
proposed over a century ago (1889) by Stephen Paget. The theory proposed that there
was something rich in the metastatic sites that promoted cancer cell growth in a similar
way that seeds tend to grow in fertile soil, i.e., that factors in the environment at a
metastatic site contributed to the targeted growth and proliferation of cancer cells.
(Stephen Paget, 1889, reviewed in Tantivejkul et al. 2004). Today this theory continues
to be relevant and supported as many factors have been found to be involved in the
attraction and growth of prostate cancer cells specifically to the bone. As an example
reflecting the important role of the bone microenvironment in supporting the growth and
12

proliferation of prostate cancer cells, bone extracts are able to induce at least a three-fold
increase in invasion by PC-3 and DU145 cells compared with brain and other tissue
extracts, which demonstrates that bone contains signiﬁcant migration and chemoinvasion
promoting factors for prostate cancer cells (Jacob et al., 1999). It is known that more
than 95% of the bone ECM is composed of collagen type I, however, many other proteins
are also deposited by osteoblasts during bone for- mation (Hauschka et al., 1986).
Osteonectin, a glycoprotein known to be secreted by osteoblasts during bone formation,
has been identiﬁed as the chemoattractant responsible for the promotion of prostate
cancer cell invasion (Jacob et al., 1999). In addition co-culture of PC-3 cells with
osteoblasts have revealed that TGF-β produced by osteoblasts stimulates PC-3 cell
migration and invasion as well as increases a2b1 and a3b1 integrins expression (Festuccia
et al., 1999).
The signaling transduction and cell to cell interactions contributing to prostate cancer
cell proliferation in the bone, are mediated through the engagement of integrin receptors
since the main component of bone ECM is collagen type I which is a ligand for a2b1 and
a3b1 integrins. Indeed greater proliferation rates for prostate cancer cells have been
observed in cells grown on collagen I compared to ﬁbro- nectin substrates; cell signaling
through phos- phatidylinositol 3-kinase (PI3K) and increased expression of cyclin D1 are
implicated in this process (Kiefer and Farach-Carson, 2001). Blocking antibodies against
the avb3 integrins can efectively reduce prostate cancer cell adhesion to crude bone
protein extract by 94% (Hullinger et al., 1998), suggesting an important role of the
integrins in the process of bone metastasis.
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Aside from the contribution of factors in the bone microenvironment, prostate cancer
cells themselves are known to be functionally involved in bone remodeling (Chung,
2003). Prostate cancer metastases are known to have an osteoblastic nature, and evidence
supports a role of bone morpho- genetic proteins (BMPs) in the course of bone metastasis
since they contribute to bone formation. In 1992, Bentley et al. reported for the first time
the expression of BMP-6, a member of the TGF-β superfamily, in prostate tissue samples
of over 50% of patients with clinically deﬁned metastatic prostate cancer, but not nonmetastatic or benign prostate samples. Overexpression of BMP-6 in metastatic prostate
cancer cells was confirmed in subsequent studies by, (Barnes et al., 1995; Hamdy et al.,
1997; Autzen et al., 1998; Thomas and Hamdy, 2000). The secretion of BMP-6, among
other proteins, by prostate cancer cells could explain targeted osteoblastic lesions during
prostate cancer metastasis since BMP-6 stimulates osteoblastic differentiation of
pluripotent mesenchymal (Ebisawa et al., 1999). Moreover, osteoblastic differentiation is
dependent on the activation of focal adhesion kinase (FAK), an immediate effector of the
integrin signaling pathway (Tamura et al., 2001).

14

Figure1.3 Components of The Tumor Microenvironment. The process of cancer
metastasis is facilitated by interactions between cancer cells and the tumor
microenvironment. These interactions are mediated by growth factors secreted by cancer
and additional components of the tumor microenvironment. The recruitment of
endothelial cells, immune cells and CAFs facilitates ECM degradation and the escape of
cancer cells into the stroma.
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TGF-β Signaling in The Prostate Microenvironment

Transforming growth factor-β (TGF-β) and its signaling effectors are extensively
studied as critical determinants of tumor cell behavior in the context of the
microenvironment. This secreted cytokine was originally named from its capacity to
induce anchorage-independent growth of normal rat kidney cells and fibroblast cell lines
i.e., to induce transformation (Moses et al. 1981, Roberts et al. 1981). The later discovery
of its multifunctional roles, not restricted to cell growth regulation, but also involving,
cell cycle control, differentiation, apoptosis, extracellular matrix formation, angiogenesis,
and immune functions, proved the name of Transforming Growth Factor Beta to be
misleading (Bottner et al. 2000, Dunker and Krieglstein et al. 2000, Lawrence et al.
1996).
Three different types of mammalian TGFβ’s have been characterized so far, TGF-β1,
TGF-β2 and TGF-β3. The most frequently upregulated in tumor cells is TGF-β1
(Schirmer et al. 2009). TGFβ’s signaling is transmitted through two types of receptors
(TβRI and TβRII) followed by downstream targeting through regulation of the SMAD
family of protein effectors. TβRI and TβRII are serine-threonine proteins kinases that
contain an extracellular ligand-binding domain, a single transmembrane domain, and a
cytoplasmic serine-threonine kinase domain (Figure 1.4). Type one receptors have a GS
domain preceding the kinases domain which is phosphorylated during signal
transduction. Type II receptors have a shorter C-terminal tail at the end of the kinase
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domain and have also a shorter extracellular domain with different distribution of
conserved cysteines. During TGF-β signal transduction, type II receptor goes through a
conformational change upon ligand binding of the extracellular domain and forms a
complex with the type I receptor which facilitates phosphorylation of the type I receptor
at its GS domain. Once phosphorylated by TβRII, TβRI phosphorylates the receptor
activated SMAD proteins (SMAD2 and SMAD 3), which form a heteromeric complex
with the co- SMAD SMAD 4 and enter the nucleus to activate or suppress target gene
expression by direct or indirect interactions with promoter regions of specific genes (Fig.
1.4). TGF-β signal transduction results in the inhibition of cell entry into S - phase by
upregulation of cyclin-dependent kinase (CDK) inhibitors (Padua and Massague, 2009).
A critical event involved in TGF-β mediated growth arrest is induction of expression of
the CDK inhibitors p15 and p21. Induction of p15 or p21 in response to TGF-β is due to
SMAD- mediated transcriptional activation. p15 prevents cell cycle progression by
interacting with complexes of CDK2 and cyclin A or cyclin E and inhibiting CDK2
kinase activity. The second inhibitor, inhibitor p21 inactivates the catalytic activity of
CDKs by interacting and inactivating CDK4 and CDK6, or by associating with cyclin D
complexes of CDK4 and CDK6. Without the action of CDKs and formation of active-cell
cycle promoters cells cannot progress through the cell cycle. TGF-β has been shown to
induce apoptosis in many cell types (Gordon and Blobe, 2008).
The SMAD pathway is the classical signaling pathway of TGF-β family members
signaling. Increased levels of SMAD 3 or SMAD 4 induce apoptosis, and dominant
negative/loss of SMAD 3 protects against cell death (Fig. 1.4). Taken together these
findings implicate SMAD signaling as the main pathway of TGF-β mediated apoptosis.
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The proapoptotic genes involved in SMAD signaling have not yet been identified.
Another pathway involved in this process is down regulation of Bcl-X and activation of
caspase 3 and 8 (Weinberg 1989). Deregulation TGF-β signaling contributes to
tumorigenesis by either loss of expression or mutational inactivation of its membrane
receptors or intracellular effectors, the SMADS. Inactivation mutations in TβRII, SMAD
2 and SMAD 4, are commonly found in many types of human cancers including, brain,
lung, breast, ovarian and pancreatic cancer. In most of colon and gastric tumors with
microsatellite instability, TβRII is inactivated by a functional mutation and in a smaller
percent for microsatellite stable colon cancers (Myeroff et al. 1995). In many other types
of human cancers like pancreatic, liver and endometrial cancer with microsatellite
instability TβR-II mutations are relatively rare (Gille et al. 2001). In the case of breast
cancer no mutations or structural dysfunctions of TβR-II have been found, but a limited
receptor expression correlates with loss of TGF-β responsiveness, while TGF-β growth
inhibition is restored in breast cancer cells by stably expressing TβR-II. TGF-β inhibits
the outgrowth of carcinomas in situ during the early stages of breast cancer while it
promotes tumor progression and enhances the ability of cancer cells to metastasize during
late stages of the disease. (Ghellal et al. 2000).
In addition to the SMAD mediated signaling there are other known mechanisms by which
TGF-β can perform multiple functions like for example the ERK, JNK, MAPK, P13 and
Rho GTPase pathways. Evidence from our laboratory and by others, have established that
TGF-β signaling can proceed without the principal effectors of the signaling pathway
SMAD 2 and 4 (Zhu, 2006). Studies involving induced apoptosis in HT58 lymphoma
cells do not reveal any impac in apoptosis (Teicher, 2007). Moreover a proteomic based
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approach identified two proteins, prohibitin and cofillin as intracellular effectors of TGFβ in human prostate cancer cells (Zhu, 2006).

TGF-β A Major Contributor To Prostate Tumorigenesis

Elevated TGF-β expression in the prostate tumor microenvironment is functionally
linked to tumor progression by increasing angiogenesis and decreasing immune responses
(Teicher. et al. 2007). TGF-β has shown pro-oncogenic functions in host immune cells,
myeloid immune suppressor cells (MISCs) by enhancing their ability to infiltrate tumors
and promote new tumor vessel formation. Studies using transgenic mice engineered with
a deleted gene encoding for a TGF-β receptor indicated that TGF-β switch from a tumor
suppressor to a tumor promoter phenotype could involve the recruitment of MISCs into
the tumor microenvironment, probably due to increased production of chemokine
CXCL5 or SDF-1/CXCR4 cytokine system by the tumor cells.
In normal prostate cancer cells and prostatic carcinoma cells TGF-β is known to induce
apoptosis in vitro and in vivo. Our laboratory have recently dissected the contribution of
TGF-β signaling in the in vivo prostate tumor microenvironment, using the
DNTβRII/TRAMP transgenic mouse model as a tool for the characterization of the in
vivo consequences of an inactivated TGF-β1signaling on prostate tumor initiation and
progression. This work established that a dysfunctional TGF-β1 signaling mechanism
results in partial loss of the inhibitory effects of TGF-β1 leading to an increase of prostate
cancer epithelial cell proliferation and angiogenesis thus promoting tumor progression
(Pu et al., 2009).
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The role of TGF-β in the inhibition of epithelial cell proliferation and promotion of
apoptosis in normal prostate epithelium and in early prostate cancer (Bello- De Ocampo
and Tindall et al., 2003). The fact that disruptions of TGF-β signaling due to either loss or
inactivation of its transmembrane receptors or intracellular effectors can lead to prostate
tumor growth rendered this cytokine to be a potential therapeutic target.
The challenge in studying TGF-β as a potential therapeutic agent relies in the ability of
this cytokine to not only suppress cancer cells growth and proliferation during the early
stages of cancer, but to promote tumor progression and metastases during the advance
stages of the disease (Padua et al., 2009). TGF-β increased expression in the tumor
microenvironment provides an advantage for tumor cell survival, because of the
angiogenic capacity of TGF-β and its potent immunosuppressive effects, including the
inhibition of natural killer cells and lymphocyte-activated killer cells. Experimental
studies with pancreatic cell lines (Panc-1) revealed a significant correlation between the
level of expression of TGF- β1 and lymph node involvement as well as depth of invasion.
Increased TGF-β levels support its involvement in the process of epithelial to
mesenchymal transition (EMT) and enhancement of the ability of invasion of pancreatic
cancer cells (Yin et al., 2006).
Transgenic adenocarcinoma of the prostate mouse model (TRAMP), a prostate cancer
transgenic mice harboring the dominant-negative mutant TGF-β type II receptor
(DNTGFβRII), manifested early malignant changes and subsequently highly aggressive
prostate tumors at a younger age, compared to control TRAMP+/Wt TGFβRII mice (Pu
et al. 2009). These prostate tumors exhibited significantly increased proliferation and
vascularity. An epithelial-mesenchymal transition (EMT)-effect was also detected in
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prostates of TRAMP+/DNTGFβRII mice, as documented by the loss of epithelial
markers (E-cadherin and β-catenin) and upregulation of mesenchymal markers (Ncadherin) ( Pu et al., 2009). Thus in vivo disruption of TGF-β signaling accelerates the
pathological changes in the prostate by altering the kinetics of prostate growth and
inducing EMT.
During early stages of tumorigenesis for prostate, breast and colon cancer, TGF-β acts
as a potent tumor suppressor and has an antiproliferative effect, inhibiting tumor growth,
but as the disease progresses to advance metastatic stage, there is a TGF-β switch to
tumor promoter, exerting a proliferative effect, increasing motility and cancer spread. The
dual role of TGF-β presents a serious clinical challenge in the treatment of many types of
cancers since TGF-β can dictate the dynamics of the therapeutic response and metastatic
spread in human cancer. Even though the therapeutic targeting of TGF-β signaling have
proven to be very challenging; today neutralizing antibodies and small molecule
inhibitors against TGF-β

have been developed and implemented in clinical trials.

However the success of these promising therapeutical agents still relies in the better
understanding of the functional switch of TGF-β from a tumor suppressor to a lethal
tumor promoter.
Angiogenesis, the formation of new blood capillary networks sprouting from preexisting vessels is an important and active process during embryonic development.
During cancer progression the development of new vasculature nourishes and facilitates
the growth of primary tumors favoring their progression and metastasis. Under normal
circumstances of angiogenesis is active during embryonic development and growth but
becomes quiescent at adult stages; however reactivation can occur during wound healing
22

and under different pathological conditions including tumor growth and metastasis. TGFβ is known to suppress or stimulate angiogenesis in a context dependent manner. The
main mechanisms by which TGF-β enhances or suppresses angiogenesis is via regulation
of vascular growth factor (VEGF). In vascular endothelial cells TGF-β can induce
expression of vascular VEGF via the promotion of fibroblast growth factor FGF-2 which
upregulate VEGF synthesis (Markowitz et al., 1995). Upon the induction of expression of
VEGF by TGF-β, VEGF can activate VEGR1 and VEGR2 which are two types of
tyrosine kinase receptors (Byrne et al., 2005). VEGR2 is involved in endothelial cell
proliferation and survival while VEGR1 have been implicated in chemotaxis and vascular
permeability (Gille et al., 2001). Several studies documented a correlation between TGFβ1 overexpression with enhanced angiogenesis around the tumor mass, leading to an
increased frequency of metastasis of prostate cancer cells (Roberts et al., 1991). In
contrast, TGF-β secreted by gallbladder tumors inhibits angiogenesis and reduces tumor
growth, suggesting its tumor suppressor function (Weinberg, 1989). The biggest
challenge in understanding this TGF-β “paradox” resides in elucidating those tumorigenic
signaling pathways by which normal tissue specification become aberrant and which of
the reciprocal signaling events mediated by TGF-β cooperate to control the
microenvironment.

Interestingly the majority of TGF-β mutations that lead to a

dysfunctional TGF-β signaling do not affect primary tumors but can enable cancer cells
to acquire EMT and invasive characteristics.
During the process of oncogenic EMT, clusters of malignant cells, loose their epithelial
characteristics and acquire self-sustained migratory and highly invasive cell phenotypes.
Thus EMT is characterized by loss of proteins associated with polarized epithelial
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phenotype and de novo synthesis of proteins associated with mesenchymal, migratory
morphology of transitioning cells. As an example, the loss of epithelial proteins such as
MUC1, E-cadherin, ZO-1, desmoplakins, and cytokeratin 18, in cells of epithelial units
defines epithelial dedifferentiation. In contrast de novo expression of vimentin is
correlated with down modulation of epithelial cytokeratins and has been proposed as
canonical marker of the fibroblastoid state of transitioning cells (Franke et al., 1982;
Boyer et al., 1989). The specific molecular mechanisms by which TGF-β induces EMT in
vivo has not been well established, but studies in vitro have indicated to be dependent of
both, Smad- and no- Smad signaling pathways. Our group demonstrated an epithelialmesenchymal transition (EMT)-effect in prostates of TRAMP+/DNTGFβRII mice
(bearing a mutant nonfunctional TGF-β receptor II), as documented by the loss of
epithelial markers (E-cadherin and β-catenin) and upregulation of mesenchymal markers
(N-cadherin) [19].

Thus in vivo disruption of TGF-β signaling accelerates the

pathological changes in the prostate by altering the kinetics of prostate growth and
inducing EMT. However, overexpression of the type I TGF-

receptor mutant that lacks

the ability to bind SMAD2/3 but is capable of activating non-Smad signaling, was
associated with increased tumorigenicity of the primary tumors, but decreased metastatic
potential of xenografted breast cancer cell lines (Tian et al., 2003; Tian et al., 2004) .
TGF-β signals in the same fashion, suggesting that TGF-β signaling may not necessary
be permanently or constitutively active at each stage of early tumor development, but
rather it depends on the specific stage of the disease, the tumor cell type and the
surrounding microenvironment.
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Figure 1.4. SMAD dependent TGF-β Signaling Pathway. During TGF-β signal
transduction, type II receptor goes through a conformational change upon ligand binding
of the extracellular domain and forms a complex with the type I receptor which facilitates
phosphorylation of the type I receptor at its GS domain. Once phosphorylated by TβRII,
TβRI phosphorylates the receptor activated SMAD proteins (SMAD2 and SMAD 3),
which form a heteromeric complex with the co- SMAD SMAD 4 and enter the nucleus to
activate or suppress target gene expression by direct or indirect interactions with
promoter regions of specific genes.
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The Role of TGF-β in Prostate Cancer Metastasis
The first and most critical step of tumor metastasis is the detachment of cancer cells
from the primary tumor and extracellular matrix (ECM) following invasion into the
surrounding tissue, resistance to anoikis, and migration via a chemoattractive path to a
metastatic site (Sakamoto and Kyprianou, 2010). A distinct molecular program is
responsible for the regulation of the adhesion, migratory and invasive properties of
disseminating tumor cells, all processes impacted by the dynamics of the cytoskeleton.
Growth factors in the tumor microenvironment have been shown to modulate the
activation of molecular pathways leading to the remodeling of the actin cytoskeleton.
Growing evidence suggests that TGF-β reduces tumor cell adhesion, and cooperates with
ErbB2 receptors to induce migration and invasion. The metastatic phenotype in cancer is
primarily dictated by ECM degradation and formation, and dramatic changes in cell
adhesion and mobility of cancer cells (Pardali and Moustakas, 2007). TGF-β can
modulate such cell- interactions with ECM and several studies have demonstrated that
TGF-β increases metastatic prostate cancer cell adhesion. TGF-β enhanced cell adhesion
is mechanistically dependent upon p38 MAP Kinase activity. P38 MAP kinases are
upregulated by TGF-β an action that modulates TGF-β dependent extracellular matrix
degradation in osteoblasts (Kleef anf Korc, 2002). The mechanism via which p38 MAP
kinase regulates TGF-β signaling is believed to be at the level of SMAD activation via
regulation of SMAD phosphorylation (Markowitz et al., 1995). Induction of p38 MAP
kinase by TGF-β activates SMAD signaling effectors suggesting a possible mechanism
for SMAD-dependent regulation of cell adhesion. Our group identified the actin binding
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protein cofilin to be a SMAD-independent intracellular effector of TGF-β in prostate
cancer cells (Zhu et al. 2006).

The Actin Cytoskeleton
The cellular cytoskeleton is composed of three main types of filaments, actin filaments,
microtubules and intermediate filaments. While microtubules and actin filaments are
directly targeted to giving structural support to the cell, intracellular trafficking and
signaling; the actin filaments are directly responsible for cell movement. Actin is
essential for cell survival because of its central role in key biological processes such as
cell division, movement, structural and mechanical support. (Pollard and Cooper, 2009).
This protein was first isolated from muscle cells and initially thought to be exclusively
involved in muscle contraction. Accounting for about 5 to 10% of total protein, actin is
known to be one of the most abundant proteins in all eukaryotic cells (Dominguez and
Holmes, 2011). At least six different actin genes are known to encode actin in mammals,
four of these genes are expressed in muscle and two in non-muscle cells. Three main
actin isoforms expressed in vertebrates include, three α-isoforms of skeletal, cardiac, and
smooth muscles and the β- and γ-isoforms expressed in nonmuscle and muscle cells.
Actin proteins are very similar in amino acid sequence and highly conserved through
evolution. Compared to eukaryotic cells, yeast have only one single actin gene, although
90% identical in amino acid sequence to mammalian actin. Some of the studies in model
organisms including Drosophila (Wagner et al., 2002 and C. elegans MacQueen et al.,
2005) have provided evidence to suggest that actin isoforms have both overlapping and
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unique cellular functions. Table 1 is a collective summary of studies in mouse models
with individual actin-isoform knockouts showing the diverse phenotypes indicating
overlapping and non-overlapping functions between the different isoforms (Hoboken,
2010).
The individual actin protein is known as (G) or monomeric actin. Each of these globular
actin monomers has binding sites that mediates head to tail interactions with two other
actin monomers generating polymers of actin monomers called (F) or filamentous actin.
Due to a rotation of 166˚ of each monomer in the actin filament resembles a double –
stranded helix with all the actin monomers oriented in the same direction. Since G-actin
is not an effective ATPase, whereas F-actin is, the main factor regulating the transition
between G- and F-actin is nucleotide hydrolysis by F-actin, as the ATP state is more
stable than the ADP state. Actin monomers join the fast-growing barbed (or +) end of the
filament in the ATP state, hydrolysis takes place in the filament, and ADP-actin
monomers dissociate faster from the pointed (or –) end. This mechanism of actin
polymerization/depolymerization is known as actin filament treadmilling (Figure 1.5)
(Wegner and Isenberg, 1983, Bravo-Cordero, 2013).
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Protein
ablated
Gene Allele
αskeletalActin
Acta1 Null

αcardiacActin
αcardiacActin

Actc1

Null

αsmoothActin
Acta2 Null
βcytoActin
γcytoActin
γcytoActin

Actb

Hypomorph

Actg1 Null
Conditionalskeletal
muscle

Transgenic
rescue
Phenotype
Pups die by 9 days of age;
exhibit muscle weakness
αcardiacActin
Full rescue
γcytoActin
Does not rescue
Embryonic/perinatal death;
disorganized myofibrils
γsmooth- Partial rescue of lethality;
Actin
hearts defective
Viable; defects in vascular
contractility and blood
pressure regulation

References
Crawford et al.,
2002
Nowak et al., 2009
Jaeger et al., 2009
Kumar et al., 1997
Kumar et al., 1997

Reduced viability; small size;
progressive deafness

Schildmeyer et al.,
2000
Shawlot et al., 1998;
Shmerling et al.,
2005
Belyantseva et al.,
2009; Bunnell and
Ervasti, 2010

Progressive centronuclear
myopathy

Sonnemann et al.,
2006

Embryonic lethal

Table 1. Actin Isoforms - Phenotypes in Mouse Models

30

Figure 1.5 Actin Treadmilling Protrusion Model. In a process known as treadmilling,
actin subunits coming from filament depolymerization at the rear of the cell are recycled
back into new filaments assembled at the front. It is the continuous assembly of actin
filaments at the leading edge of cells what generates the protrusive extensions of the
cytoplasm.
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Figure 1.5 Actin Treadmilling Protrusion Model
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Cytoskeletal Actin Remodeling and Cell Movement
Among the many critical functions of the cellular actin network cell movement is
required as early as in embryonic development for the processes of morphogenesis,
neurite movement in the developing nervous system, chemotactic movement of immune
cells and wound healing (Gurniak et al. 2005).Without actin remodeling and cell
movement the development and survival of multicellular organisms wouldn’t be possible
in any tissue environment. In a process known as treadmilling, actin subunits coming
from filament depolymerization at the rear of the cell are recycled back into new
filaments assembled at the front. It is the continuous assembly of actin filaments at the
leading edge of cells what generates the protrusive extensions of the cytoplasm allowing
the cell to move and determining the direction of cell movement. The dynamic net of
actin filaments and its rapid polymerization and depolymerization at the leading and rear
ends allow the cell to attach to a substrate, contract its body, push forward and move in
response to stimuli from the microenvironment (Figure 1.6). (Yilmaz and Christophori,
2010).
The actin cytoskeleton remodeling network is composed by a series of actin binding
proteins which cooperatively bind, nucleate, sever, and incorporate new actin monomers
into new actin filaments allowing the cell to develop specific movement, adhesion, and
invasion structures such as lamellopodia, filopodia and invadopodia (Figures; 1.6 and
1.7). Inside the cellular cytoskeleton actin is known to interact with more than 60 actinbinding proteins (ABPs) which regulates the assembly and disassembly leading to the
remodeling of actin cytoskeletal networks. Cells extending their leading end depend
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mainly on the activity of four core actin remodeling proteins: 1) The Arp2/3 complex,
mediating the initiation of new filaments as branches on preexisting filaments (Pollard
and Beltzner, 2002); 2) capping proteins which terminate filament growth (Cooper and
Shafer, 2000); 3) ADF/cofilin severing actin filaments and promoting branching and
depolymerization of existing actin filaments (Bamburg et al. 1999) and 4) profiling
catalyzing the exchange of ADP to ATP, refilling the pool of ATP actin monomers and
elongating the filaments (Shluter et al. 1997).
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Figure 1.6 Cytoskeletal Remodeling and Cell Movement Structures. The dynamic net
of actin filaments and its rapid polymerization and depolymerization at the leading and
rear ends allow the cell to attach to a substrate, contract its body, push forward and move
in response to stimuli from the microenvironment.
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Figure 1.6 Cytoskeletal Remodeling and Cell Movement Structures
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Cofilin in Control of Cell Movement
Among the key actin remodeling proteins needed for cytoskeletal reorganization at the
leading edge of moving cells, cofilin have proven to be the main regulator of the actin
dynamics since de novo synthesis of actin filaments in the cell is not favorable due to the
instability of actin dimers and trimmers.
The binding of cofilin to the ADP- actin filament induces stress to the actin filament,
changes the twist of the actin filament and promotes severing and disassembly of the
filament (Bamburg, 1999). Cofilin severing activity on already existing filaments allowed
free barbed ends for the rapid addition of new actin monomers resulting in the rapid
growth of filaments and filament branching (Figure 1.7). It is known that the rapid
polymerization of actin filament on a compartmentalized cell cannot continue without
rapid depolymerization, thus in moving cells cofilin severing activity is critical for the
formation of new actin filaments needed for the development of specific migration
structures and Bamburg , 2010). Indeed ADF/Cofilin has proven to be an essential
protein, whose deletion leads to lethal defects in centrosome translocation and cytokinesis
(Gunsalus et al., 1995), while in contrast, cofilin overexpression have been shown to
increase cell movement. (Aizawa et al., 1996). In addition to the promotion of new
filament polymerization at the leading edge, cofilin is known to promote filament
branching by providing free barbed for nucleation via the ARP2/3 complex resulting in
membrane protrusions from which invasion structures such as lamellopodia and filopodia
are born. In parallel action, cofilin supports contractions at the rear end of the cell
through focal depolymerization of F-actin and the regulation of actin myosin assembly,
37

by inhibiting binding of myosin II to F-actin. These actin/myosin regulated cell
contractions at the rear end of the cell are critical to pull the cell forward finalizing the
cell motility cycle. The multiple roles of this single protein in the control of cytoskeletal
actin dynamics makes cofilin a critical modulator of processes as diverse as biological
embryonic development and pathologic tumor development and metastasis.

Regulation of Cofilin Activity

The function of cofilin is temporally and spatially regulated via three types of
mechanisms, dephosphorylation of cofilin at Serine 3 residue; the release of cofilin from
PtdIns (4, 5)P2 and the release of cofilin from cortactin (Mizuno, 2012). Although, the
binding of cofilin to PtdIns (4,5)P2 inactivates cofilin by sequestering the protein at the
plasma membrane and the release from PtdIns(4,5)P2 via its hydrolysis by phospholipase
C (PLC) renders cofilin available for the initiation of actin severing , the activity status
of cofilin is directly regulated via phosphorylation and dephosphorylation of a single
serine residue at position 3 (Arber, 1998). Cortactin binding comprises an alternative
mechanism to negatively regulate cofilin’s activity, however this mechanism is known to
be specific to the development of invasion targeted protrusions such as invadopia
(Weaver et al., 2006, Buccione et al., 2009, Linder et al., 2011). Phosphorylation of
cofilin on Ser3 inhibits its binding to G actin (monomeric actin) and F-actin (filamentous
actin) and severing of the actin filament at the leading edge of migrating cells. Several
studies have documented differences in the cellular distribution of phosphorylated and
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non-phosphorylated cofilin; being non-phosphoylated cofilin present in motile and
invasive protrusions such as lamellopodia and filopodia of epithelial cells and
phosphorylated cofiin uniformly distributed in the cytoplasm with the exception of the
leading edge (Bravo et al., 2013). Four kinases have the ability to phosphorylate cofilin in
vivo, LIM kinase -1, LIM kinase -2, (LIMK1, LIMK2), TES kinase 1 and TES kinase 2
(TESK1, TESK2) (Moriyama et al., 1996, Arber et al., 1998). LIMKs are known to be
the dominant kinases involved in the regulation of actin dynamics, while TESKs are
known to be involved in the process of focal adhesion via integrins signaling (Mizuno et
al. 2012). The Rho-associated, coiled-coil containing protein kinase 1 (ROCK1), is
responsible for LIMK-2 phosphorylation and activation. LIMK1 and 2 are activated via
phosphorylation at Thr508 and Thr505 by several types of kinases including ROCK,
PAK1, PAK2, PAK4, MRCKα and MAPK-activated protein kinase 2. ROCK1,
phosphorylates and activates LIMK-2 in response to extracellular stimuli such as
epidermal growth factor (EGF), leading to cytoskeletal reorganization via the activation
of the RhoA/ROCK1 signaling pathway (Figure 1.8). Cofilin dephosphorylation at Ser3
and reactivation is performed mainly by Slingshot (SSH) phosphatase and chronopin
(CIN) a phosphatase recently found to be specific for cofilin dephosphorylation (Niwa
et al.,2002, Mizuno et al., 2012). Actin polymerization regulated by cofilin
dephosphorylation/activation is a convergence point in the intracellular signaling network
through which extracellular stimuli impact actin cytoskeleton, invasion and apoptosis
Alterations in cofilin and its signaling modifiers have been reported in invasive breast
and ovarian cancer (Nishimura et al., 2010).
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Figure 1.7 Cofilin Severing Activity. The binding of cofilin to the ADP- actin filament
induces stress to the actin filament, changes the twist of the actin filament promoting
severing and disassembly. Cofilin severing activity on already existing filaments allowed
free barbed ends for the rapid addition of new actin monomers resulting in the rapid
growth of filaments and filament branching. The ARP2/3 protein complex serve as
nucleation sites for new actin filaments while profilin incorporates actin monomers at the
growing end of new actin filaments.

40

Cell Membrane Protrusion

Cell Membrane
ARP2/3

Cytoplasm

Profilin
ARP2/3
Cofilin

Profilin

Cofilin
ARP2/3

Cofilin

Profilin

+ end

Actin Filament
Monomeric Actin
Cofilin
ARP/23
Profilin

Figure 1.7 Cofilin Severing Activity
41

- end

Figure 1.8 Regulation of Cofilin Activity/Function. The Rho-associated, coiled-coil
containing protein kinase 1 (ROCK1), is responsible for LIMK-2 phosphorylation and
activation in response to extracellular stimuli, leading to cytoskeletal reorganization via
the activation of the RhoA/ROCK1 signaling pathway. Phosphorylation of cofilin by
LIMK-2 at a specific Serine 3 residue, inhibits cofilin actin severing activity.
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Cofilin in Cancer

The critical role of cofilin in the modulation of cell movement and invasion lead to
studies correlating cofilin activity and cancer. Growing evidence revealed the
overexpression of cofilin protein, as well as genes encoding key regulators of the cofilin
signaling pathways in different types of cancers like breast, lung, pancreatic and ovarian
cancer (Sinha et al. 1999, Nishimura et al. 2010). As an example cofilin was found to be
overexpressed in the highly invasive C6 rat glioblastoma cell line, A549 human lung
cancer cells and human pancreatic cancer cells (Sinha et al., 1999, Gunnersen et al., 2000,
Keshamouni et al., 2006). Studies in mammary carcinoma cells involving the expression
of a constitutively active LIMK1 that increases the amount of phospho-cofilin in vivo
demonstrated the inhibition of actin polymerization and motility in response to EGF,
confirming the impact of alterations in key regulators of cofiling signaling on cancer cell
movement (Zebda et al., 2000). Additional studies confirm this phenomenon in various
cell lines since the overexpression of LIMK1 lead to the inhibition of cell movement in
neuroblastoma cell lines and Ras-transformed fibroblasts (Sahai et al., 2001, Myer et al.
2005). In contrast, a dominant-negative LIMK1 results in increased movement in
neuroblastoma cell lines. Moreover, in vivo studies demonstrated the metastatic potential
of orthotopic mammary tumor cell inoculation to be directly related to the functional
output of the cofilin pathway (Wang et al. 2006). As an example, tumors harboring
suppressed cofilin activity due to cells in which cofilin pathway activity due to LIMK1
overexpression exhibited decreased invasion and metastasis and were associated with
increased survival; in contrast, tumors derived from cells with increased cofilin pathway
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activity (LIMK dominant negative) showed increased invasion and metastasis and were
associated with decreased survival (Wang et al. 2006). This evidence suggests a link
between tumor cell behavior and expression patterns of genes encoding cofilin and key
regulators of the cofilin pathway and provided a new insight into the interaction of
cytoskeletal modulators with factors in the tumor microenvironment. However the
precise mechanisms via which cofilin modulates cytoskeletal remodeling in response to
stimuli from the tumor microenvironment, and how those signals are interpreted by
cancer cells are still not well understood.
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CHAPTER II

RATIONALE AND SPECIFIC AIMS

Rationale

Metastasis is the cause of 95% of cancer-related deaths. Cancer metastasis is mediated
by cellular interactions in response to signals from the tumor microenvironment affecting
cytoskeletal actin polymerization and depolymerization leading to the modulation of cell
adhesion, migration and invasion. TGF-β is known to be highly expressed in the prostate
tumor microenvironment. This growth factor is the quintessential negative growth factor
via its ability to inhibit proliferation and induce apoptosis. In addition to TGF-β’s role as
a tumor suppressor this growth factor is known to switch roles and become a tumor
promoter at late stages of the disease via the promotion of cell invasion, angiogenesis and
the modulation of cell adhesion and migration.

The actin binding protein cofilin is directly functionally responsible for the remodeling
of actin filaments and filopodia formation toward cytoskeletal reorganization, ultimately
driving cell motility. Previously, evidence from or group, demonstrated that the small
actin binding protein and main regulator of cytoskeleton actin dynamics cofilin to be a
SMAD independent effector of TGF-β’s. Understanding how cancer cells interprete
TGF-β signals from the microenvironment, is significant for defining the mechanism via
which TGF-β function is switched from a growth suppressor to a metastasis promoter.
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Thus, I hypothesized that there is an association between cofilin and prostate cancer
metastatic progression that may be of significant predictive and targeting value in
metastasis. Hence, the main goals of my work (presented on this thesis) are the following:
1) to dissect the molecular mechanisms by which the actin binding protein cofilin
modulates actin cytoskeleton remodeling in prostate cancer cells , towards cell
movement, attachment and invasion towards prostate canncer metastasis, 2) to study
cofilin as a SMAD independent effector of TGF-β and the effect of the tumor
microenvironment in cytoskeletal remodeling, cell migration, adhesion and invasion in
prostate cancer cells.

Specific Aims

Secific Aim 1: Determine the consequences of a mutation in cofilin phosphorylation
(regulation) site Ser 3 in cofilin expression and phosphorylation and the molecular
mechanisms by which TGF-β modulates cofilin activity in prostate cancer (PC-3) cells.
To gain a mechanistic insight into the role of cofilin in directing TGF-β responses
towards cytoskeletal remodeling. This study will pursue the identification of molecular
players directly involved in cofilin modulation by TGF-β.

Specific Aim 2: Determine the biological function of a mutation at cofilin
phosphorylation site Ser3 in prostate cancer (PC-3) cells. The effect of a mutation in
cofilin phosphorylation site on prostate cancer cell migration, adhesion and filopodia
formation is assessed on WTCFL and S3ACFL PC-3 mutants mimicking the
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constitutively active form of cofilin; as well as in S3DCFL mutants mimicking the
constitutively inactive form. The impact of S3ACFL mutation on prostate cancer cell
invasion in the presence of CAFs will allow the interrogation of the function of cofilin
phosphorylation (regulation) in prostate cancer cell migration, invasion and adhesion in
the context of the tumor microenvironment. This study will investigate the role of the
tumor microenviroment in the regulation of biological processes targeting the actin
cytoskeleton afecting prostate cancer progression to metastasis.

Specific Aim 3: Determine the in vivo consequences of a mutation on cofilin
phosphorylation site and its effect on prostate cancer progression to metastasis. To
determine the in vivo role of cofilin in prostate cancer metastasis, an experimental
metastasis assay is performed. This study will extend and confirm the in vitro studies
described in Specific Aim 2 and will enable the identification of the impact of cofilin
S3A mutation on the process of prostate cancer in an in vivo physiologically relevant
setting.

Specific Aim 4: Determine the value of cofilin expression in prostate cancer metastasis.
These experiments will evaluate the expression profile of total and phosphorylated cofilin
in the transgenic adenocarcinoma of the mouse model (TRAMP) and in primary and
metastatic prostate tumors from the same patient cohort.

48

CHAPTER III

EXPERIMENTAL APPROACH

Cell Lines
The androgen independent human prostate cancer cell line PC-3, originally established
from a patient with bone metastasis and known to be highly tumorigenic and metastatic in
xenograft models (Kaighn et al. 1979) was obtained from the American Type Culture
Collection (Manassas, VA). PC-3 cells were cultured in RPMI 1640 medium containing
2.05 mM L-glutamine, 2 g/liter sodium bicarbonate and 2 g/litter glucose (Invitrogen,
Carlsbad, CA) together with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml
streptomycin at 37˚C under a humidified atmosphere of 5% CO2. To test our findings in a
secondary androgen responsive prostate cancer cell line we used the androgen sensitive
prostate cancer cell line LNCaP overexpressing the TGF-β receptor II (LNCaPTRII)
previously generated in our laboratory (Guo et al. 1999). LNCaPTRII cells were cultured
under the same conditions as the PC-3 cell line. Primary cultures of human prostate
cancer associated fibroblasts (CAFs) were established from radical prostatectomy
specimens (from prostate cancer patients). Five distinct primary cultures of human
prostate cancer associated fibroblasts from prostatectomy specimens were generated.
Characteristics of CAFs (PCa-Str2-6) were analyzed by western blotting for the
expression of AR, prostate specific membrane antigen, (PSMA), epithelial markers
cytokeratin-18 (CK-18) and c-Met and stromal marker α-smooth muscle actin in a
comparative analysis with human prostate cancer epithelial cell lines (LNCaP, PC-3,
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DU145). CAFs were maintained in SCBM CC 3204 (Lonza, Walkersville, MD) at 37˚C
under a humidified atmosphere of 5% CO2.
Isolation of Prostate Cancer Associated Fibroblasts (CAFs)

Human prostate tumor tissue was severed by a scalpel in multiple small fragments in
SCGM (SCBM+5%FBS) medium in a tissue culture plate. Culture plate was incubated
undisturbed for 5-7 days (medium was refreshed). After 1-2 weeks, plates were washed
with PBS, trypsinized for ~2 minutes to detach only stromal cells. Floating cells were
collected, centrifuged, and resuspended and cultured in SCGM, incubated for 3 days,
trypsinized again. The process was repeated in T175 flask. Cells were harvested and
frozen in multiple vials and stored in liquid nitrogen. Vials were cultured in SCGM and
tested for cyto differentiation markers by western blotting

Transfections
The S3A cofilin mutant prostate cancer cell line was generated by site directed
mutagenesis in PC-3 cells. A point mutation targeting Ser 3 phosphorylation site was
induced by PCR. To mimic a dephosphorylated (constitutively active) form of cofilin
(S3ACFL mutants), a substitution of a Serine on position 3 to Alanine was generated.
WT and S3ACFL mutant forms of cofilin were introduced into PC-3 cells via stable
transfection. S3D cofilin mutation, mimicking the constitutive phosphorylated (inactive)
form, was introduced in PC-3 cells via transient transfection. Expression vectors for S3D
cofilin were generous gifts from Dr. Sergei Krupenko, (MUSC, Charleston, SC). Cells
were transfected with pXJN-HA/cofilin vector DNA using the Effectene Transfection
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Reagent (QIAGEN 301425, Hilden, Germany). Cofilin expression was silenced in PC-3
cells by using the siRNA sequence targeting cofilin codons 64-84. A siRNA containing a
two single-nucleotide mutation of cofilin sequence (C71G and A73U) was used as
control.

Cell Viability
To assess cell viability we used the MTT assay. Cells (104/well) were seeded into 96well plates and incubated in growth medium (24 hrs). After incubation with the MTT
solution for 4 hrs, and after dissolving formazan crystal absorbance was read at 490nm
(Bio-RAD 680, USA) and the colorimetric reaction product was quantitated
spectrophotometrically.

Migration Assay
The migration ability of WTCFL and mutants S3ACFL (active form of cofilin),
S3DCFL (inactive form of cofilin) prostate cancer cells was analyzed via wound assay.
Cells (104 cells/well) were seeded in 6 well multiwell plates, allowed to grow to 60-70%
density of cell monolayer and a wound was induced using a pipet tip. After wounding,
cells were exposed to TGF-β (Recombinant Human TGF-β1, R&D Systems, MN, USA)
(5ng/ml; 24hrs) in the presence or absence of TGF-β (Human LAP TGF-β1 Antibody,
R&D Systems, MN USA) neutralizing antibody. The number of migrating cells was
counted in three different fields, under microscopic examination.
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Adhesion Assay
A subconfluent cell culture of wild type and mutants S3ACFL, S3DCFL PC-3 cells
was treated with TGF-β (5ng/ml, 24 hrs) at 37ºC. Cells (40,000 cells/well) were seeded in
6-well plates pre-coated with fibronectin (0-8 μg/ml). After 30 min incubation (at 37ºC)
non adherent cells were removed and adherent cells were fixed with ice cold methanol
(5min). The number of cells attached was evaluated in three different fields under
microscopic examination.

Fibronectin Coating
Fibronectin, Humanplasma (1mg) (Calbiochem) was thaw by placing the vial in a 37˚C
water bath undisturbed until completely thawed. Pre-warmed, sterile, serum free 16140
RPMI (Invitrogen) culture medium was added to the solution to a final volume of 20ml to
yield a fibronectin work solution of 50µg/ml. The fibronectin work solution (1ml) was
added to each well of a 6 multiwell plate, gently swirling the solution to evenly coat the
bottom of the well. The plates were incubated at room temperature for 45 minutes to
allow binding of the fibronectin to the surface of the well. Finally fibronectin work
solution was removed by tilting the plate and gently aspirating with a sterile pipet.

Evaluation of Cell Invasion
(a) Matrigel Invasion Assay: The invasion potential was evaluated using a
Biocat Matrigel Transwell Chamber (Beckon Dickinson, Franklin Lakes, NJ). Cells were
seeded into the upper chamber of a transwell insert pre-coated with matrigel in serumfree medium (50,000 cells/well). After 24hrs non-invading cells were removed from the
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upper chamber and invading cells were stained with Diff-Quick Solution (IMEB Inc., San
Marcos, CA).
(b) Matrigel Cell Tracking:

Human prostate cancer-associated fibroblasts

(CAFs) and PC-3 prostate cancer cells were independently grown in medium containing
SCBM or RPMI respectively. SCBM medium containing CellTracker™Green CMFDA
dye (5μM) (Invitrogen USA) and 1640 RPMI medium containing CellTracker™ Orange
CMTML (Invitrogen USA), were added to CAFs and PC-3 cells, respectively (45mins).
The CellTracker™ Green CMFDA labeled cell suspensions of CAFs were placed into the
inner circle of underside membrane of a Biocat Matrigel Transwell Chamber precoated
with matrigel. Inserts were placed in 12-wells in Biocat Matrigel Transwell Chambers in
the absence or presence of TGF-β ligand (5ng/ml). CellTracker™ Orange CMTML
labeled WT and S3ACFL PC-3 cells were seeded in the upper chamber and after 24hrs
invading cells were detected using an epifluorescence Nikon Eclipse E600 microscope
(Nikon, Melville, NY).

In-vitro Co-culture Assay
Human prostate cancer associated fibroblasts (CAFs) were grown in the inner
membrane circle of Biocat Matrigel Transwell Chamber inserts and after 24hrs, inserts
were transferred in Biocat Matrigel Transwell Chambers in absence/presence of TGF-β
neutralizing antibody 5ng/ml. Prostate cancer epithelial cells were seeded into the upper
chamber and after co-culturing for 24hrs invading cells are stained with Diff-Quick
Solution (IMEB Inc, San Marcos, CA) and visualized under light microscopy.
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Western Blot Analysis
Cell pellets and lung tissue were lysed in RIPA buffer (50mM Tris-HCl, pH7.4,
1%NP40, 0.25% Na-deoxycholate, 150 mM NaCl, 1mM EDTA, 1mM PMSF, (Sigma
P8340 protease inhibitor). Protein (30µg) as a cell lysate or tissue homogenate was
fractioned by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on gradient gels
and transferred to Immuno-Blot PVDF membranes. The membrane was blocked with
0.05% Tween-20 and 5% defatted milk (1hr at room temperature) followed by incubation
to the respective primary antibodies in the same buffer overnight at 4˚C with gentle
shaking. After 24 hrs the immunoblot was developed with a secondary antibody
conjugated to horseradish peroxidase (1hr at room temperature) and proteins bands were
detected using the ECL plus Detection System (GE, Amersham, UK). The
chemiluminescent image was captured by autoradiography. The antibodies used were:
anti-cofilin (1:10,000) (Sigma Aldrich, St. Louis, MO), phospho–cofilin (Ser 3) (1:10,00)
; anti-LIMK-2( 1:1000) (Cell Signaling, Danvers, MA) and (GFP1:100) (Santa Cruz
Biotechnology, CA).

Immunoprecipitation Assay
For the immunoprecipitation experiments, PC-3 cells were transfected with Flagtagged WTCFL, S3ACFL, and T25A CFL, and cells were grown in CSS medium for
24hrs. Cells were subsequently treated with TGFβ1 (for 6hrs) in the absence or presence
of MEK inhibitor PD98095. Whole cell lysates were subjected to immunoprecipitation
with the anti-Flag antibody, and Western blots with the specific antibodies as follows:
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Cells were lysed by sonication in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 1 mM EDTA) supplemented with
protease inhibitor cocktail, 1 mM PMSF and 10 units/ml of DNase I (New England
Biolabs). After centrifugation at 21,000  g for 12 min at 4°C, the supernatants/clarified
lysates were isolated and their protein concentrations measured. Aliquots of the clarified
lysates (~600 ug of protein each) were then pre-cleared with Protein G Plus/Protein
Agarose beads (Calbiochem) and 1 ug of normal mouse IgG (Santa Cruz) for 1 h, then
incubated with anti-acetylated lysine antibody (Cell Signaling) and Protein G
Plus/Protein (30 μl), 18 h at 4°C. After collection by centrifugation and removal of
supernatant, the beads were then washed three times with RIPA buffer supplemented
with protease cocktail inhibitors, 1 mM PMSF and 200 ug/ml ethidium bromide. After
removal of the final wash, equal portions of RIPA and 2X SDS sample buffer were added
to the beads and immunoprecipitated proteins were released by heating at 95°C for 5 min.
Equal volumes of each sample were resolved by SDS-PAGE (8%).

Immunofluorescence Staining
Cells (7x104cells/well) were seeded in 6-well plates containing a glass cover slit and
exposed to TGF-β (5ng/ml, 24hrs). Cells were fixed in cover slit by adding ice cold
methanol-free formaldehyde (15mins), followed by two washes with PBS and
permeabilization with 2ml of Triton X-100 (0.1% v/v) (5mins). After permeabilization
cover slits were exposed to Rhodamine Phalloidin for fluorescent staining of filamentous
actin (Invitrogen). Cofilin expression was detected by blocking the coverslit on goat
serum buffer for 1hr followed by incubation with primary rabbit anti-cofilin antibody
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(1:10,000) for 24hrs at 4˚C (Sigma Aldrich, St. Louis, MO). Cover slits were
subsequently removed, washed with PBS and incubated with Alexa Fluor 488
(Invitrogen) (1hr). Images were processed using a fluorescence Nikon Eclipse E600
microscope (Nikon, Melville, NY).

Experimental Metastasis Assay
The metastatic potential of WTCFL and S3ACFL mutant PC-3 cells was examined in
vivo by the tail vein injection-experimental metastasis assay. Male nude mice (6-wks old)
(Harlan Laboratories Inc., Indianapolis, IN) were maintained in sterile cages in pathogenfree environment. Animal experiments were performed under protocols approved by the
Institutional Animal Care and Use Committee. GFP labeled WTCFL and S3ACFL PC-3
106 cells were injected into the tail vein of mice (n=6/cell line). At 4-wks postinoculation, lungs were excised and metastatic lesions to the lungs were counted under a
dissection microscope.
Wild type and mutant S3ACFL PC-3 cells were cultured in T-75 flasks. Cells were
harvested by triptinization and cell suspensions were submitted to centrifugation (1,000
RPM, 5 minutes). After centrifugation the supernatant was discarded and 1ml of fresh
growth medium was added. A cell suspension containing 106 cells per ml was prepared
as described above. A total of 1ml of cell suspension was injected into the lateral
saphenous tail vein as followed:
(a) Mice were restrained via the injection of the anesthetic (Ketamine, conc.
100mg/ml) (0.1ml per 10 gm of body weight).

56

(b) Periferal vasodilatation of tail vein was induced by submerging the mouse tail
into a glass beaker containing warm water (5 minutes).
(c) The injection area was disinfected with ethanol swipes and tourniquet-like
pressure was applied to the bottom portion of the tail.
(d) A 28 ½ gauge needle containing 1ml of cell suspension was injected into the
vein at a slight angle.
After injection needle was removed and pressure was applied at injection site.

Preparation of Lung Tissue Homogenates
Lung tissue homogenates were prepared as followed: Right and left lungs were
transferred into a Dounce and Potter-Elvehjem homogenizer containing chilled RIPA
homogenization buffer (50mM Tris-HCL, pH 7.4,150mM NaCl, 1mM PMSF, 1mM
EDTA, µg/ml aprotinin, 5 µg/ml leupeptin, 1% Triton X-100, 1% sodium deoxycholate
and 0.1% SDS). Protease and phosphatase inhibitors were added and samples were
subjected to freeze-thawing (2cycles) and centrifugated (at 18,300xg, 10 min at 4˚C).
Supernatants were subjected to Western Blot analysis.

Immunostaining Analysis of Paraffin Embedded Human Prostate Specimens
Human Prostate Specimens: Formalin fixed paraffin embedded specimens
of human local and metastatic prostate cancer were obtained from the
University of Kentucky Cancer Center Tissue Biobank with Institutional
Review Board Approval. Sections (4µm) were affixed to glass slides,
deparafinized and rehydrated.

Total cofilin and p-cofilin expression was
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detected using the following antibodies: (C8736) Anti - cofilin from Sigma
Aldrich (St. Louis, MO), (3311) Phospho – cofilin (Ser 3) from Cell Signaling
Technology (Danvers, MA). Palladin expression was detected using (10853-1AP) PALLD palladin antibody fom Proteintech Group. E- Cadherin
expression was detected using (24E10) E-Cadherin rabbit Ab from Cell
signaling Technology (Danvers, MA). Sections where incubated with the
corresponding primary antibodies (1:50 to 1:100) overnight at 4ºC). After two
washes with 1x TBS - 0.1% Triton – X slide sections were incubated with
Mollipore (21537) IHC select immunoperoxidase secondary detection system
(1hr) followed by incubation with Millipore Streptaviding HRP (1hr at room
temperature). Peroxidase activity was detected by applying Diaminobenzidine
(DAB) and counterstained with hematoxylin. Slides were analyzed under a
light microscope followed by pathological evaluation. Images were
photographed at 40x magnification.

TRAMP Mouse Model: The transgenic adenocarcinoma mouse prostate
(TRAMP) was used to investigate the correlation between cofilin and
phosphorylated cofilin expression and prostate cancer progression. TRAMP is
considered a suitable model of prostate tumorigenesis. As shown below,
TRAMP transgenic male mice develop prostate cancer from prostatic
intraepithelial neoplasia (PIN) into metastatic androgen independent
carcinoma in a manner resembling the clinical progression of human prostate
cancer patients.

The TRAMP transgene is in the C57BL/6J genetic
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background. TRAMP mice are transgenic mice that express SV40T/t antigen
under the prostate specific rat probasin promoter. Tissue sections from (16,
20, 24, 28 wks) TRAMP prostate tumors of increasingly aggressive stage
were subjected to immunohistochemical analysis as above.

Reproduced from: the greenberglab.fhcrc.org

Figure 3.1: TRAMP Mouse Model of Prostate Cancer Progression

Statistical Analysis
Statistical analyses are performed with GraphPad Prism 5 for Windows (GraphPad
Software, San Diego, CA). Data are presented as + Standard Error of the Mean (SEM).
Numerical values are the mean of three independent experiments. Statistical evaluation of
the data is performed using the Student t test and Two-way analysis of variance for
multiple comparisons. Significant difference is defined at P value < 0.05.
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CHAPTER IV

RESULTS

Cofilin Activity Directs TGF-β Mediated Actin Severing in Prostate Cancer Cells
Phosphorylation of cofilin (CFL) on Ser3 inhibits its binding to G actin (monomeric
actin) and F-actin (filamentous actin) and severing of the actin filament at the leading
edge of migrating cells. Constitutively active (dephosphorylated) forms of cofilin were
generated in PC-3 prostate cancer cells by mutagenesis via substitution of a Serine on
position 3 to Alanine (S3ACFL mutants) and a Threonine to Alanine at position 25
(T25ACFL

mutants).

Immunoprecipitation

analysis

of

phosphorylated

protein

associations in response to TGF-β, revealed that the S3ACFL mutation specifically
conferring cofilin dephosphorylation, promotes its association with actin (enhancing
filament severing), while the T25ACFL mutation, (impairing Threonine phosphorylation)
had no effect on the association of p–cofilin with actin (Figure 4.1). Moreover, the
presence of MEK inhibitor (PD98059) abrogated the TGF-β mediated association
between p-Erk and cofilin (Figure 4.1). Mutational activation/cofilin dephosphorylation
(S3ACFL or T25ACFL), or loss of cofilin expression (shCFL) had no significant
consequences on prostate cancer cell viability (Figure 4.2). The S3A cofilin mutation, as
expected, abrogated its phosphorylation by LIMK-2, without affecting total cofilin
expression (Figure 4.3 A); there was a compensatory upregulation of LIMK-2 levels in
the S3ACFL PC-3 cells compared to wild type cofilin PC-3 (WTCFL) (Figure 4.3 A,
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Panel A). Figure 4.3 panel B reveals the endogenous upregulation of downstream
signaling effectors RhoA and ROCK1 induced by the introduction of cofilin mutations;
both S3DCFL and S3ACFL cells exhibited a significant increase in protein expression for
RhoA and ROCK1, compared to WTCFL cells. In response to TGF-β, there was a
transient induction in phosphorylated cofilin within 3 to 6hrs, that was preceded by a
significant increase in ROCK 1 and Rho A levels, in the WTCFL but not in the S3ACFL
cells (Figures 4.3, panels C and D).
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Figure 4.1 Specificity of S3A Active Cofilin Protein Associations in Response to
TGF-β. PC-3 cells were transfected with Flag tagged WTCFL, S3ACFL, or T25ACFL,
after growing in CSS medium (24hrs), cells were treated with TGFβ1 (5ng/ml) for 6hrs
with or without PD98095. Cell lysates (50µg of protein) were subjected to
immunoprecipitation with anti-Flag antibody, and subsequent Western blotting with the
indicated antibodies. Actin and phosphorylated proteins p-Erk and p-cofilin show
enhanced association with WCFL in response to TGF-β. S3A CFL mutation confers
constitutive dephosphorylation and thus cofilin fails to undergo TGF-β-mediated
interaction with actin. In comparison, the T25A CFL mutation impairs threonine
phosphorylation, but has no effect on the phosphorylated cofilin-actin association in
response to TGF-β.
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Figure 4.1 Specificity of S3A Active Cofilin Protein Associations in Response to
TGF-β.
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Figure 4.2 Effect of Cofilin Mutational Activation or Loss on Prostate Cancer Cell
Death and Endogenous Cofilin Expresion. Panels A: The effect of a mutation on
cofilin phosphorylation site Ser3 or cofilin silencing was assessed by MTT assay. Neither
shRNA silencing of cofilin expression or inducing a mutation on cofilin phosphorylation
site has any effect on cell viability. Panel B: endogenous cofilin expression was assessed
by Western blotting analysis in prostate cancer cell lines: PC-3, LNCaP, DU145 and C42 as well as in the breast cancer cell line MCF7. The androgen independent PC-3 and
androgen sensitive LNCaP prostate cancer cell lines together with the breast cancer cell
line MCF7 showed higher levels of endogenous cofilin compared to DU145 and C4-2
prostate cancer cell lines.
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Figure 4.2 Effect of Cofilin Mutational Activation or Loss on Prostate Cancer Cell
Death and Endogenous Cofilin Expresion.

A.

B.
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Figure 4.3 Effect of S3A Mutation on Cofilin Phosphorylation Events in PC-3 Cells.
Effect of TGF-β on cofilin, p-cofilin and LIMK-2 protein expression in prostate cancer
cells. Panel A, Upregulation of LIMK-2 protein in mutant S3ACFL PC-3 cells.
Treatment with TGF-β (5ng/ml) increased LIMK-2 and p-cofilin expression in wild type
PC-3 cells and decreased the expression of LIMK-2 in the S3ACFL cells. Panel B,
Western blotting indicating elevated RhoA and ROCK1 protein in S3ACFL PC-3. Panels
C and D, Treatment with TGF-β increased RhoA and ROCK1 levels in WTCFL cells and
decreased expression of both proteins in S3ACFL cells. GAPDH was used as loading
control. Molecular weights for individual proteins are shown on the right.
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Figure 4.3 Effect of S3A Mutation on Cofilin Phosphorylation Events in PC-3 Cells.

A.

B.
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C.

D.
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Active Cofilin Dictates Prostate Cancer Cell Migration and Invasion Responses to
TGF-β
To determine the effect of a mutation in cofilin phosphorylation site on prostate cancer
cell migration, we assessed the migration ability of WTCFL and S3ACFL mutants
mimicking the constitutively active form of cofilin; as a functional control, S3DCFL
mimicks the constitutively inactive form. The S3A cofilin mutation resulted in a
significant increase in PC-3 cell migration (Figure 4.4). There was a decrease in cell
migration in the mutant S3DCFL cells (Figure 4.4). As shown on Figure 4.5, treatment
with TGF-β (24 hrs) led to a significant decrease in cell migration for WTCFL cells;
functional blocking of TGF-β by the neutralizing antibody, restored migration capacity to
control levels in WT cells (Figure 4.5). The impact of S3ACFL mutation on prostate
cancer cell invasion was interrogated in the context of the tumor microenvironment. The
quantitative data from the invasion assay indicate no significant difference in the invasion
potential of S3ACFL cells compared to WTCFL PC-3 cells (Figure 4.6). The increase in
invading cell number in response to exogenous TGF-β, was abrogated by the presence of
the neutralizing antibody against TGF-β, in both WTCFL and S3ACFL cells (p<0.05).
The reactive stroma contributes to prostate cancer progression through the cancerassociated fibroblasts that facilitate metastasis (Yang et al, 2007; Jung et al, 2013). To
assess whether the effect of cofilin on prostate tumor cell invasion was TGF-β-dependent
as mediated from surrounding tumor associated fibroblasts, prostate cancer cell invasion
was evaluated in in vitro co-cultures. Fluorescent labeled PC-3 prostate cancer epithelial
cells (red) were co-cultured with labeled human prostate cancer associated fibroblasts
(green) in the upper chamber of a matrigel pre-coated transwell insert (24hrs) (Figure 4.7,
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upper panel). As shown on Figure 4.7 (lower panel), only prostate tumor epithelial cells
invaded the matrigel. There was no significant difference in cell invasion between
WTCFL and S3ACFL cell lines (but there was a decrease in the S3D mutant cells). In the
presence of human prostate cancer associated fibroblasts (CAFs) however, there was a
significant increase in the number of tumor epithelial cells invading, for both WTCFL
and S3ACFL PC-3 cells. The S3D CFL mutation (phosphorylation) had no effect on
prostate cancer cell invasion regardless of TGF-β status (Figure 4.7) (lower panel).
Simultaneous exposure to the TGF-β neutralizing antibody (5ng/ml) resulted in further
significant increase in the S3ACFL invasion potential (p< 0.004), (while it reduced
WTCFL PC-3 cell invasion), demonstrating that only active cofilin was able to
functionally direct TGF-β signaling (secreted by the CAFs in co-cultures) towards
enhanced invasive behavior while it further increased S3ACFL migration (lower panel).
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Figure 4.4 Cofilin Activation Status Dictates Prostate Cancer Cell Migration.
Mutation in cofilin phosphorylation site Ser3 mimicking the constitutively active form of
cofilin (S3ACFL) significantly increased prostate cancer cell migration compared to
WTCFL (p<0.03). Prostate cancer cells harboring the inactive form of cofilin (S3DCFL
mutation) exhibited a significant reduction in migration capacity compared to S3ACFL
cells (p<0.006). Values shown are the number of migrating cells from two independent
experiments performed in triplicate.
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Figure 4.4 Cofilin Activation Status Dictates Prostate Cancer Cell Migration.
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Figure 4.5 S3ACFL Mutation Enhances Prostate Cancer Cell Migration by passing
TGF-β. Upper panel, representative images of increased cell migration ability for
S3ACFL PC-3 cells compared to WTCFL cells (24hrs). TGF-β treatment significantly
decreased WTCFL cell migration (p<0.0008), but it had no significant effect in S3ACFL
cells. Loss of TGF-β (in presence of neutralizing antibody) restored the WTCFL PC-3
cell migration capacity (to control levels), while it increased S3CFL mutant cell
migration (p=0.005). Cell (Lower panel) cell migration was also analyzed on the
androgen sensitive prostate cancer cell line LNCaPTRII overexpressing TGF-β type II
receptor. TGF-β treatment significantly decreased LNCaPTRII cell migration (p=0.0013).
Loss of TGF-β (in presence of neutralizing antibody) restored LNCaPTRII cell migration.

73

Figure 4.5 S3ACFL Mutation Enhances Prostate Cancer Cell Migration by passing
TGF-β.

LNCaPTRII
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Figure 4.6 Cofilin Navigates Invasive Response to TGF-β. The invasive response of
prostate cancer cells to TGF-β was assessed in the matrigel assay. The mutation on
cofilin phosphorylation site had no significant effect on PC-3 cell invasion (black
barographs). In response to exogenous TGF-β, there was an increase in WTCFL PC-3
cell invasion potential, but not in S3ACFL cells (p=0.03). Loss of TGF-β (by neutralizing
antibody) led to a significant decrease in the invasion potential for both WTCFL and
S3ACFL cells (p=0.04 and p=0.004, respectively). (Lower panel) cell invasion was also
analyzed on the androgen sensitive prostate cancer cell line LNCaPTRII overexpressing
TGF-β type II receptor. TGF-β treatment significantly increased LNCaPTRII cell
invasion.
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Figure 4.6 Cofilin Navigates Invasive Response to TGF-β.
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Figure 4.7 Co-Culture of S3ACFL PC-3 cells with Human CAFs Markedly
Enhanced Prostate Cancer Cell Invasion. Panel A .Characteristics of 5 different
prostate cancer associated fibroblasts CAFs were analyzed by Western blotting (PCaStr2-6) in a comparative analysis with human prostate cancer epithelial cell lines
(LNCaP, PC-3, DU145) for the expression of AR, prostate specific membrane antigen,
(PSMA), cytokeratin-18 (CK-18), α-smooth muscle actin and c-Met. As shown in lanes
2-6, only the cancer associated fibroblasts were positive for the expression of the stromal
marker, α-smooth muscle actin whether only prostate cancer cells were positive for the
epithelial markers CK-18 and c-Met. Panel B, representative image of fluorescent labeled
WTCFL PC-3 prostate cancer cells (red) and human cancer associated fibroblasts (green)
co-culture (1:1) (48hrs). Panel C, matrigel invasion in co-cultures of WTCFL, S3ACFL
and S3DCFL with CAFs in the presence or absence of a neutralizing TGF-β antibody.
Quantitative assessment of invading cells indicates that only active cofilin (S3A
mutation) directs a further increase in TGF-β mediated cell invasion (derived from
CAFs). In WTCFL PC-3/CAFs, and S3ACFL PC-3/CAFs co-cultures after 24hrs, CAFs
significantly increased prostate cancer cell invasion for both WTCFL and S3ACFL cells
(p=0.004 and p=0.007) (lower panel lanes 1 and 2). Continuous secretion of TGF-β by
the reactive microenvironment (in presence of TGF-β neutralizing antibody), induced a
further increase in the number of invading S3ACFL cells (p=0.008), while it decreased
WTCFL cell invasion. Values are the average from two independent experiments in
triplicate.
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Figure 4.7 Co-Culture of S3ACFL PC-3 cells with Human CAFs Markedly
Enhanced Prostate Cancer Cell Invasion.

A.
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Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal Remodeling
Cell adhesion is directly dependent on cofilin activity and cytoskeletal actin since
depolymerization and polymerization of new actin filaments is required for filopodia
formation (Arjonen et al. 2011). We subsequently investigated the effect of S3A mutation
on prostate cancer cell adhesion to the extracellular matrix (ECM) component fibronectin
and filopodia formation. The S3A mutation significantly increased cell adhesion to
fibronectin compared to control WTCFL cells (Figure 4.8). This correlated with
cytoskeletal remodeling as indicated by fluorescence staining of F actin and formation of
filopodia (Figure 4.9). Confocal microscopy revealed an increased number of filopodia
protrusions in S3ACFL PC-3 (arrows) compared to WTCFL PC-3 cells (Figure 4.9).
High cofilin expression was detected at cell membrane regions populated by filopodia
(Figure 4.10). Treatment with TGF-β led to a significant decrease in S3ACFL cell
adhesion (Figure 4.9), and a reduction in filopodia protrusions (Figures 4.9 and 4.10).
To determine whether this cofilin co-localization with filopodia is dependent on
endogenously derived TGF-β from the surrounding prostate cancer associated fibrobalsts
(reactive stroma), we subsequently profiled the cofilin/rhodamine phalloidin cocolocalization, in S3ACFL prostate epithelial cancer cells co-cultured with human CAFs.
As shown on Figure 4.10, cofilin (green) colocalizes with filopodia protrusions (arrows)
and loss of TGF-β resulted in increased actin/cofilin colocalization (yellow) with
filopodia protrusions in S3ACFL cells in this reactive stroma-tumor microenvironment.
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Figure 4.8 Active Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal
Remodeling, an Effect Impaired by TGF-β. The effect of S3A mutation on prostate
cancer cell adhesion was assessed via cell adhesion assays to fibronectin. S3A mutation
significantly increased cell adhesion to fibronectin compared to WTCFL control cells
(p=0.0003). TGF-β treatment led to a significant decrease in S3CFL cell adhesion
(p=0.0004), but no effect on WTCFL cells. Values shown are the mean (+/-SEM) of three
independent experiments performed in triplicates. Statistical significance set at a P value
of p<0.005.
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Figure 4.8 Active Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal
Remodeling, an Effect Impaired by TGF-β.
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Figure 4.9 S3A Mutation Enhances PC-3 Filopodia Formation. The effect of S3A
mutation on prostate cancer cells filopodia formation was assessed via Phalloidin staining
of actin filaments. Active cofilin enhances filopodia formation; representative images of
confocal microscopy (40x) show increased number of filopodia protrusions in S3ACFL
PC-3 (arrows) compared to WTCFL PC-3 cells. Treatment with TGF-β (5ng/ml; 24hrs)
decreased filopodia protrusions in S3ACFL cells. Filopodia were quantitated as we
recently described (Zhu et al, 2012). Five random fields were examined for each cell line
and values shown represent the mean +/- SEM from three independent experiments.
Statistical significance is defined at P<0.01.
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Figure 4.9 S3A Mutation Enhances PC-3 Filopodia Formation.
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Figure 4.10 Cofilin Co-localization with Filopodia is Dependent on TGF-β Derived
from The Surrounding Prostate CAFs (stroma). Images of cofilin/rhodamine
phalloidin colocalization, in S3ACFL prostate epithelial cancer cells co-cultured with
CAFs. Cofilin (green) colocalizates with filopodia protrusions (arrows). Loss of TGF-β
(in presence of neutralizing antibody) resulted in increased actin/cofilin colocalization
(yellow) and filopodia protrusions in S3ACFL cells.
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Figure 4.10 Cofilin Co-localization with Filopodia is Dependent on TGF-β Derived
from The Surrounding Prostate CAFs (stroma).
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Active Cofilin Enhances Prostate Cancer Metastasis In Vivo
In the experimental metastasis assay, prostate cancer cells harboring the S3ACFL
mutation exhibited an increased metastatic ability in vivo, compared to WTCFL cells, as
determined by the higher number of lung metastases produced (Figure 4.11).
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Figure 4.11 Cofilin Constitutive Activation Promotes Prostate Cancer Metastasis.
Panel A, Male nude mice (n=12) were inoculated with GFP-labeled PC-3 cells (parental,
WTCFL and S3ACFL) via tail vein injections. Panel B, Metastatic lesions to the lungs
were assessed at 4-wks post-inoculation. S3ACFL cells generated a significantly higher
number of metastases compared to control PC-3 cells (p=0.04). Values show the number
of metastatic lesions to the lung/mouse for each cell line. Western blots of mouse lung
tissue homogenates and cell lysates indicate the GFP presence in all samples (positive
control).
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Figure 4.11 Cofilin Constitutive Activation Promotes Prostate Cancer Metastasis.
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Figure 4.12 Schematic diagram illustrating the regulatory impact of cofilin on TGFβ functional switch towards prostate cancer cell migration, invasion and metastasis.
Under conditions of constitutive active (S3A mutant) cofilin, TGF-β produced by the
reactive

stroma/microenvironment

(cancer

associated

fibroblasts),

unable

to

dephosphorylate cofilin confers increased tumor cell aggressive characteristics and
metastatic potential.
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Figure 4.12 Schematic diagram illustrating the regulatory impact of cofilin on TGFβ functional switch towards prostate cancer cell migration, invasion and metastasis.
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Cofilin Overexpression Correlates with Prostate Cancer Progression to Metastasis
TRAMP transgenic mice develop prostate adenocarcinoma with increasing age,
resembling progression of human prostate cancer to metastasis. Analysis of cofilin
expression during prostate cancer progression in the TRAMP model, revealed an
association between high cofilin immunoreactivity and tumor aggressiveness with
increasing age (16-28wks) (Figure 4.13). Quantitative analysis indicated a significant
increase in cofilin expression in metastatic tumors (28-wks) compared to early stage
tumors and normal prostate (16-wk WT) (Figure 4.13). Immunohistochemical profiling
of cofilin in human prostate tissue specimens from a patient cohort with localized and
metastatic disease to the lymph nodes, indicated a striking increase in cofilin expression
in metastasis compared to primary cancer in the same patient (Figure 4.14). Characteristic
images of cofilin immunoreactivity in poorly differentiated prostate tumors and
metastasis are shown on Figures 4.14A and 4.14B, respectively). There were no
significant differences in the expression of p-cofilin or palladin proteins between primary
and metastatic prostate cancer (Figure 4.14, panels C and D).
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Figure 4.13 Cofilin Profiling in TRAMP Mouse Model. TRAMP transgenic mice
develop prostate adenocarcinoma with increasing age, resembling progression of human
prostate cancer to metastasis. Prostate sections of increasing grade and metastatic tumors
(16-28wks) were profiled by immunostaining for cofilin expression; WT mouse prostate
tissue (16wks) was used as control. (magnification X40). Quantitative evaluation of
cofilin immunoreactivity, as determined by the H-scoring, shows a significant increase in
metastatic tumors from 28-wks old TRAMP mice (p=0.001) compared to early stage
tumors.
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Figure 4.13 Cofilin Profiling in TRAMP Mouse Model
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Figure 4.14 Cofilin Expression Profile in Human Prostate Cancer.
Panel A, H&E staining and cofilin immunostaining in serial sections of prostate tumors
(Grade 3 and Grade 5) from two different patients. A striking increase in cofilin
immunoreactivity was detected in the higher Grade prostate tumor. Panel B,
characteristic image of a metastatic lesion to lymph nodes exhibiting intense cofilin
immunoreactivity, compared to the primary tumor from the same patient (showing
absence of cofilin expression). Magnification X, Panel C indicates representative images
of immunostaining for cofilin, p-cofilin, E-cadherin and palladin on primary and
metastatic prostate cancer. Panel D, quantitative analysis of protein immunoreactivity
(from Panel C). There was significant increase in cofilin levels in prostate cancer
metastasis compared to primary tumors (p=0.005).
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Figure 4.14 Cofilin Expression Profile in Human Prostate Cancer.
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CHAPTER V

DISCUSSION

Cofilin has been previously identified as a Smad independent effector of TGF-β
apoptosis signaling in prostate cancer cells (Zhu et al. 2006). TGF-β increases LIMK-2
activity (upregulates ROCK1 and RhoA kinases) leading to phosphorylated cofilin and
decreasing actin cytoskeleton severing in prostate cancer cells. The present study
indicates that while TGF-β mediates a striking reduction in the migratory capacity of
WTCFL PC-3 cells, it fails to exert such an effect in the mutant S3ACFL cells (Fig.
4.12). As cofilin is unable to be phosphorylated by LIMK-2 (directed by TGF-β) in
S3ACFL mutants, our findings suggest an alternative pathway via which TGF-β is
modulating cofilin activity. One may argue that TGF-β signaling does not exclusively
target modulation of cofilin severing activity, but it rather impairs prostate cancer in the
early stages of disease progression by putting the “breaks” on cofilin activity
(phosphorylation status). During the late stages of tumor progression, a mutation
conferring constitutive activation of cofilin, enables escape from the TGF-β control of
actin severing, towards enhanced migratory and invasive properties (Figure 4.12). This
argument supports a sustained role of cofilin as an effector of TGF-β, potentially
navigating its functional swinging from growth suppressor to a metastasis promoter
during prostate tumorigenesis. An acquired enhanced motility at an early stage may
provide S3ACFL mutants the initial input required to escape the primary tumor site,
reach a nearby vascular tissue, intravasate, travel through the blood stream and
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metastasize to a distal site. The optimal conditions will sustain colonization and growth
and will allow prostate cancer cells to invade and proliferate into a secondary tumor. Via
the secretion of cytokines and growth factors cancer cells now take advantage and
modulate the new microenvironment to their favor supporting tumor growth and
progression to metastasis. The high levels of TGF-β in the prostate microenvironment
evidences the active tumor stroma dynamics. Cancer cells can secrete cytokines and
respond to extracellular signals from the tumor microenvironment, however in response
to TGF-β, cancer associated fibroblasts are going to differentiate into myofibroblasts
which are known to be involved in extracellular matrix degradation facilitating the
metastatic spread of adjacent prostate cancer cells. These dynamic interactions between
cancer cells and the stroma microenvironment (inflammatory cells, vessels, fibroblasts
and components of the ECM) in turn impact tumor invasion (Desmoulière et al 2004, De
Wever and Marel 2003).
The results, described in this dissertation, support the notion that impairing cofilin
activity (due to spontaneous mutations on phosphorylation site), is an early event
promoting cancer cell migration and metastatic spread. The findings also indicate that
cofilin severing activity towards actin cytoskeletal remodeling and increased prostate
cancer cell-ECM adhesion and migration is dependent on TGF-β. Interestingly enough,
we also report here that cancer associated fibroblasts substantially enhance the invasive
properties of prostate cancer cells with mutant cofilin (constitutively active), regardless of
TGF-β deprivation. This evidence provides a proof-of-principle on a direct pro-invasive
crosstalk between surrounding cancer associated fibroblasts and prostate cancer cells with
TGF-ß functioning as a tumor suppressor by activating the RhoA/ROCK1 signaling,
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leading to phosphorylation and activation of LIMK-2.This impairs cofilin severing
activity, cytoskeletal reorganization and formation of filopodia, decreasing tumor cell
migration (illustrated schematically on Figure 4.12 ). During prostate cancer progression
the TGF-ß functional switch from a growth suppressor to metastasis promoter, is
programmed by activated cofilin that enables actin cytoskeleton remodeling, conferring
aggressive tumor cell behavior (Figure 4.12).
Cancer metastasis is mediated by cell-matrix interactions engaging components of the
extracellular matrix (ECM), to form adhesion complexes and actin polymerization to
form cell protrusions to adhere to ECM, directing cell migration. Characterization of the
actin cytoskeleton dynamics in tumor metastasis will enable a new platform for targeting
significant protein interactions towards impairing metastatic progression, as well as
identification of new markers of therapeutic response in advanced diseases. This study
identified the functional contribution of cofilin to the metastatic process in prostate
cancer. The results revealed significant differences in actin remodeling proteins,
migration, invasion and adhesion potential between the wild type and mutant
(constitutively active) S3ACFL PC-3 harboring a mutant cofilin phosphorylation site.
S3ACFL conferred an increase in the migration potential compared to wild type PC-3
cells, suggesting that cofilin regulation is linked to acquisition of an enhanced migratory
phenotype of prostate cancer cells. Considering that cofilin is directly responsible for the
remodeling of actin filaments and filipodia formation toward cytoskeletal reorganization,
ultimately driving cell motility, the finding that neither mutation S3A or T25A had any
significant consequences on prostate cancer cell invasion might not be surprising. Indeed,
cell migration relies on the coordinated remodeling of the actin cytoskeleton and leading
100

edge protrusions of moving cells are formed by lamellopodia and filopodia. (Arjoen et al.
2011). In breast cancer cells, cofilin activation by epidermal growth factor (EGF), leads
to increased number of actin filament barbed ends. It is the elongation of barbed ends via
the polymerization of G actin monomers that generates new actin filaments and dynamic
filament branching at the tip of the leading edge (Zebda et al. 2000). In this study we
found a marked increase in filopodia formation in S3ACFL PC-3 cells and lack of actin
association with constitutively active cofilin, suggesting alterations in cofilin
phosphorylation/dephosphorylation in prostate cancer cells interfere with its function in
actin severing. Considering that filopodia can enable not only cell motility, but also
facilitate attachment to the ECM and to a distal site promoting colonization and
formation of secondary tumors (Arjonen et al. 2011), our findings support the concept
that mutational activation of cofilin, besides enhancing cell movement, can also promote
cell attachment to fibronectin, possibly by remodeling critical cell-ECM adhesion sites
and regulatory protein associations.
This study establishes that constitutively active cofilin results in actin cytoskeleton
remodeling impacting prostate cancer cell adhesion, migration and invasion in response
to TGF-β. Cofilin is thus a non-canonical effector of TGF-β signaling, capable of
coordinating the cellular responses to TGF-β towards metastasis. The significant
association between cofilin overexpression/activation with prostate tumor invasive and
metastatic behavior, supports a potential predictive and targeting value for cofilin in
cancer metastasis.
The immunoshistochemical profiling identified a direct association between cofilin
overexpression and cancer progression to metastasis in the TRAMP mouse model of
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prostate tumorigenesis. Moreover, my studies demonstrate a significant increase in cofilin
expression in human prostate cancer metastasis (to lymph nodes), compared to primary
tumors. Changes in cofilin expression have been reported in other human malignancies
including colon and ovarian cancer (Wang et al. 2007, Sadako et al. 2010, Popow et. al
2012). Loss of the epithelial marker E-cadherin is associated with a more invasive
phenotype in prostate cancer cells and high grade and metastatic prostate cancer, as
previously established (Umbas et al. 1992). In addition immunohystochemical profiling
of total cofilin in tissue microarrays (TMAs) from breast and colon cancer showed high
levels of expression of total cofilin supporting again, a potentially significant vale for
cofilin as a biomarker not only for prostate cancer but for different types of cancers.
Ongoing studies in collaboration with Dr. Andre Balla at the University of Illinois,
include the profiling of total cofilin and phosphorylated cofilin in TMAs from a larger
prostate cancer patient cohort with advanced disease.
We should consider the involvement of additional actin binding proteins acting together
to facilitate actin cytoskeletal remodeling since cofilin severing activity is not sufficient
to support the novo synthesis of actin filaments at the leading edge of moving cells.
Without actin nucleation by the Arp2/3 complex, the presence of actin bundling proteins
and the addition of actin monomers by profilin, cytoskeketal remodeling will not
progress. We found an increase in the actin bundling protein palladin together with
cofilin in metastatic human prostate cancer specimens compared to primary prostate
cancer from the same patient, supporting the role of additional actin remodeling proteins
in the progression of prostate cancer towards metastasis. Since CAFs, or activated
fibroblasts present in the stroma surrounding solid tumors are capable to promote
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invasion and metastasis of cancer cells, the mechanisms regulating the activation of the
fibroblasts and the initiation of invasion are of great interest. Interestingly, the
upregulation of the cytoskeletal protein, palladin, has been found to be upregulated in
stromal myofibroblasts surrounding many solid cancers and in expression screens for
genes involved in invasion. Studies involving a pancreatic cancer model, investigated the
functional consequence of overexpression of exogenous palladin in normal fibroblasts in
vitro and its effect on the early stages of tumor invasion. These studies demonstrated that
that palladin expression can impart myofibroblast properties, in turn promoting the
invasive potential of these cells with invadopodia-driven degradation of extracellular
matrix (Brentnall et al., 2012). Additional elegant studies, have confirmed that the
conversion of fibroblasts into active cancer associated fibroblasts also called
myofibroblasts, not only is induced by TGF-β, but also involve an increase in the
expression of palladin (Rönty et al. 2006). The secretion of extracellular proteins,
proteases, cytokines, and growth factors by myofibroblasts results in the modulation of
the ECM (Powell et al., 1999; Tomasek et al., 2002). We can consider a scenario in
which TGF-β in the tumor microenvironment mediates the upregulation of palladin not
only in tumor associated fibroblasts favoring their conversion into myofibroblasts and the
degradation of the ECM but also the upregulation of palladin in cancer cells.
Upregulation of the actin bundling protein palladin, together with an upregulation of
cofilin severing activity, may provide prostate cancer cells with enhanced actin
remodeling activity facilitating their escape into the stroma, once the ECM barrier have
been disrupted by active myofibroblasts. While TGF- β’s role in myofibroblastic
differentiation have been widely studied, the signaling pathways involved in cytoskeletal
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modulation are not well characterized. My work identified for the first time that TGF- β
induced expression of palladin and cofilin is regulated via signaling pathways targeting
cytoskeleton remodeling in prostate cancer cells. These results are of high clinical
significance since the use of biological markers for better prognosis and treatment of
prostate cancer patients relies on the identification of specific proteins correlating with
metastatic potential. The immunohystochemical analysis for the expression of cofilin in
primary human prostate cancer tissue together with the actin bundling protein palladin
and the presence of active myofibroblasts via α-SMA staining have the potential to be
exploited as a novel and patient specific tool for predicting prognosis in prostate cancer
patients. The overexpression of unphosphorylated (active) cofilin, together with the
overexpression of palladin and the presence of activated fibroblast at the primary tumor
can be used as a marker for prostate cancer metastatic burden. Therefore, I am proposing
the development of a novel screening technique involving not only the screening for
prostate specific antigen PSA at early stages of prostate cancer but in combination with
cofilin, palladin and α-SMA biomarkers. This technique will supplement PSA screening
and allow to better predict which patients are at higher risks of developing metastatic
prostate cancer and will require a more aggressive treatment. Indirect support for this
approach is gained from recent evidence correlating cofilin expression with ovarian
cancer progression, and a longer progression free survival in low cofilin patient cohort
(Nishimura et al. 2011) together with findings showing that paladin is overexpressed in
the CAFs of several tumor types including pancreas, breast, lung, kidney, and ovary but
is expressed at lower levels in normal stromal fibroblasts (Goicoechea et al., 2010, Ronty
et al., 2006).
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In addition to the potential use of cofilin as a potent biomarker for predicting prognosis,
the use of cancer specific RhoA and ROCK1 kinase inhibitors for the temporally
regulation of cofilin severing activity will allow to inhibit prostate cancer metastatic
spread at early stages of the disease without compromising the overall cofilin activity
which is necessary for the survival and growth of non-cancer cells. Via the inhibition of
RhoA and ROCK1 kinases at early stages of the disease in mutant cancer cells, cofilin’s
phosphorylation by LIMK in response to TGF-β is blocked, suppressing cofilin enhanced
severing activity and the development of an enhanced migratory phenotype thus
suppressing metastatic spread. Our results revealed a suppression of the RhoA/ROCK1
signaling pathway in the wild type cells, however mutant S3ACFL being unable to be
phosphorylated by LIMK in response to TGF-β were able to escape its tumor
suppression. Another therapeutic approach based on our results would be the use of
genetic screening to determine patients with mutations in cofilin phosphorylation site
predisposing these patients to an aggressive cancer due to the loss TGF-β tumor
suppression at early stages of the disease. This approach would allow a better
understanding of prostate cancer dynamics at early stage of disease for each individual
patient and will translate in the development of personalized treatment depending on the
genetic background, in terms of cofilin mutations that could facilitate cell motility and
adhesion to the ECM, together with mutations regulating intercellular adhesion, such as
like E-Cadherin and N-Cadherin, as well as cytoskeletal ECM linking proteins such as
integrins.
An insight into each of the steps preceding metastatic spread reveals a common
denominator for the majority of primary solid tumors; the loss of cell to cell adhesions,
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detachment from the basement membrane and the acquisition of an enhanced migratory
phenotype; each of these events being directly dependent on cytoskeletal changes and
ECM remodeling. It is not surprising for the cell cytoskeleton to play such important role
in the determining the fate of cancer since it comprises the most extended network for
communication between signaling proteins inside and outside a cell. It is the constant
traffic of signals facilitated by motor proteins such as Dynein through the cell
cytoskeleton what facilitates cell movement in any tissue environment. Although many
efforts focused on the tumor suppressor and oncogenic pathways in cancer allowing
specific cell types to undergo malignant transformation, we must always recognize that
most of prostate cancer patients do not die from primary tumors and less attention have
been directed to the cytoskeletal changes allowing cancer cells to undergo metastasis
spread. Our focus on the main regulator of the cytoskeleton dynamics cofilin allow us to
explore many alternatives to not only block the overall migratory potential of prostate
cancer cells but the transport of signaling proteins and the transduction of signaling
cascades that facilitates the process of cancer metastasis. One of the possibilities includes
as discussed before, targeting cofilin activity for the suppression of cancer migration at an
early stage, however another possibility includes the regulation of cofilin severing
activity spatially for the delivery of specific therapeutically agents along the cytoskeletal
network. By modulating the activity actin binding proteins like cofilin and palladin we
can attain the selective remodeling of the cellular actin network to our advantage, the
same way cancer cells remodel the cytoskeleton to obtain an enhanced metastatic
potential. Therapeutically this will translate into the possibility to selective transport
drugs such as small molecular inhibitors to specific targets inside the cell or to block
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signaling molecules like transcription factors from reaching their targeted genes many of
them tumor promoter genes and oncogenes promoting tumor progression.
One of the most important candidates for this therapeutic technique based on
cytoskeletal modulation and transport would be the AR. Via the disruption of nuclear
actin network in the same way microtubule-targeting drugs, such as the Vinca alkaloids
and taxanes, have been used to target the mitotic spindle checkpoint, arresting cell cycle
progression leading to apoptosis it could be possible to attack castration resistant tumors
via the disruption of AR translocation into the nucleus. To support this idea, previous
studies from our group comparatively analyzed TMAs from Docetaxel-treated and
untreated prostate cancer patients for prostate specific antigen (PSA) and AR
immunoreactivity. The study revealed that in addition to blocking cell division, the
microtubule stabilizing drug Docetaxel impairs AR translocation into the nucleus (Zhu et
al., 2010). Although it is clear that microtubules and actin cytoskeleton have distinct
roles, there have been studies that evidence an interaction between these two, moreover it
have been found that an intact microtubule cytoskeleton is needed to maintain the
polarized distribution of actin protrusions at the leading edge of migrating fibroblasts
(Vasiliev et al., 1970). Thus the targeting microtubules/actin interactions emerges as a
novel therapy not only for the suppression of cancer cell movement and progression to
metastasis but for the delivery of drugs into the cell without affecting overall toxicity and
overcoming drug resistance via the modulation of signaling cascades routes. The best
evidence supporting the interactions between the microtubule and actin network is
provided by the Rho family of GTPases, which can regulate both actin filaments and
microtubules (Wittmann and Waterman, 2001). Based on our results we can propose a
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mechanism in which RhoA can suppress the actin polymerization while promoting the
stabilization of microtubules at the same time via the activation of ROCK1 kinase
resulting in the phosphorylation of cofilin and the inhibition of actin filaments which in
turns help stabilize the microtubule network. Thus, we can submit the notion that the
activity of RhoA is regulated in the same time by microtubules and actin. The activation
of cofilin severing activity and actin polymerization will promote RhoA/ROCK1 leading
to phosphorylation of cofilin and the inhibition of actin polymerization resulting on
microtubule stabilization. Microtubule stabilization will inhibit RhoA /ROCK1 in a
negative feedback reactivating cofilin severing activity. By transiently inhibiting
RhoA/ROCK1 we can stimulate cofilin activity, stabilizing microtubule and altering the
microtubules tracks required by protein effectors for the transduction of signaling
cascades (Figure 5.1).
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Figure 5.1 Potential Mechanism for Microtubule Stabilization and Transcriptional
Inhibition via Targeting of Cytoskeletal Remodeling. RhoA activation suppresses
actin polymerization while promoting microtubules stabilization at the same time via the
activation of ROCK1 kinase resulting in the phosphorylation of cofilin and the inhibition
of actin filaments which in turns help stabilize the microtubule network. Microtubule
stabilization results in the inhibition of signaling molecules and transcription factors from
reaching their targeted genes leading to tumor suppression.
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Figure 5.1 Potential Mechanism for Microtubule Stabilization and Transcriptional
Inhibition via Targeting of Cytoskeletal Remodeling
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Cell to cell communication also play critical role on cancer progression. A collection
of cell surface proteins recognize signals from the microenvironment and nearby cells.
Filopodia structures not only are rich in cell adhesion proteins, they are responsible for
probing the pericellular environment for chemotactic factors and other molecular signals
in the ECM that enable and direct the movement of the cell and for receiving and
transmitting information between cells the same way dendrites are used by neuronal cells
to receive and conduct the electrochemical stimuli from other neural cells inside the brain
(Horace, 2011). This work demonstrates that the modulation of cofilin actin severing
activity affects the development filopodia protrusions of prostate cancer cells, a
significant discovery, since cells utilize filopodia to communicate within the tumor
microenvironment towards metastasis. Our results demonstrated that a mutation on
cofilin phosphorylation site (S3A) can enhances filopodia protrusions bypassing TGF-β
tumor suppression. This study reveals for the first time that cytoskeletal changes impact
the ability of prostate cancer cells to recognize signals from the tumor microenvironment.
Proteomics studies performed in collaboration with Dr. Haining Zhu, demonstrated an
overexpression of EMMPRIN (extracellular matrix metalloproteinase inducer) in the cell
surface of prostate cancer PC-3 cells compared to benign BPH-1 (Zhu. et al, 2011).
EMMPRIN silencing markedlyimpaired cancer cell adhesion and filopodia formaton.
One may consider that the overexpression of EMMPRIN result as cancer cells develop a
more aggressive and motile phenotype and develop filopodia. Each filopodium serves as
a template for the cell surface protein EMMPRIN to be exposed to be recognized by
nearby cells recruiting cells bearing the EMMPRIN receptor on the cell surface in the the
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same way as immune cells are recognized by and communicate with antibodies in the
circulation by exposing their epitopes at the cell surface (Figure 5.2).
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Figure 5.2 Role of Filopodia in Tumor Microenvironment Signal Recognition and
Transduction.

The development of filopodia structures in cancer cells provides a

template for the cell surface protein EMMPRIN to be exposed and be recognized by
nearby cells, recruiting cells expressing the EMMPRIN receptor to the tumor site.
Recruitment of ECM remodeling cells like CAFs, leads to ECM degradation and tumor
invasion.
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Figure 5.2 Role of Filopodia in Tumor Microenvironment Signal Recognition and
Transduction.
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What is more, the EMMPRIN interaction with its receptor on target fibroblasts, is
known to upregulate MMP-1 (matrix metalloproteinase 1) transcription facilitating tumor
invasion and metastasis (Sidhu et al., 2004). Consistent with these findings we have
shown enhanced invasion of prostate cancer cells in the presence of cancer associated
fibroblasts. By targeting cofilin severing activity and cellular cytoskeleton remodeling we
can impair the development of filopodia on tumor cells inhibiting EMMPRIN exposure,
the recognition by cancer associated fibroblasts and their recreation to the tumor site,
therefore inhibiting ECM degradation, tumor invasion and metastasis. What is more,
studies have demonstrated that therapeutic treatment of pancreatic cancer that reduces the
cancer-associated fibroblasts is more effective in prolonging survival than standard
chemotherapy that targets only the cancer cells (Olive et al., 2009, Sahai, 2010, Xu et al.,
2010). Thus deviating signaling cascades to inhibit the recruitment of fibroblast to the site
of cancer via the modulation of cytoskeletal remodeling, can be exploited as a pre chemotherapeutic treatment to prolong patient survival. The above therapeutic approach
will change the way we look at and treat cancer today. Since 1889, the seed and soil
theory has proposed that the presence of factors in specific organ are responsible for the
growth of only certain types of cancers. Based on my findings, I proposed a new
hypothesis in which there is not the presence of unique factors in the site of metastasis,
that promote selective metastatic spread to a specific organ but, the ability of cancer cells
to receive, transduce and alter signaling pathways on nonmalignant cells in the new
tumor site. Once cancer cells has taken control of the new microenvironment they can
signal non-malignant cells to secrete growth factors and immunosuppressive cytokines
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needed by cancer cells to grow and proliferate on a foreign environment. This study
proposes that the future of cancer therapy, could rely on
the targeting of molecular pathways leading to the development of specific signaling
structures such as the cofilin signaling pathway to block filopodia structures and the
target of cell surface signaling proteins like EMMPIRIN. Thus by blocking the ability of
cancer cells to recognize, transduce and deliver signals to the tumor site, we should be
able to indirectly block, not only the process of EMT, ECM degradation and invasion,
intravasation into circulation at early stages but the recruitment of blood vessels via
stimulation of VEFG, and responses to growth factors stimuli like TGF-β on already
established tumors, changing the fate of tumor cells to die rather than grow and
proliferate.

Clinical Significance
For many years, prostate specific antigen (PSA) screening have saved many lives,
since it translated on early prostate cancer detection and treatment. However many times
it has also led to over-diagnosis and overtreatment of prostate cancer patients (Etzioni et
al., 2012). Another critical problem about the use of PSA is the limited predictive
accuracy for predicting outcomes after treatment and for making clinical decisions about
the type and intensity of therapies. Although Gleason Score information have been used
by pathologists to understand how a particular case of prostate cancer can be treated and
patients likely to survive following a diagnosis of prostate cancer, this approach is based
exclusively on the architectural pattern of the glands of the prostate tumor, does not
provide information on therapy selection and does not count with a mechanistic
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foundation that can guide the best sequences or combinations of agents in targeting
specific biomolecules. As a result, patients are currently grouped by clinical stage or
treatment status as: with or without bone metastasis, resistance to androgen ablation
therapy or not, with or without chemotherapy (Logothetis et al. 2013). Even though the
patient's Gleason score with his PSA level and the clinical stage estimated by the
physician can be used to estimate the likelihood that that patient has localized or locally
advanced prostate cancer of different types, there is an imperative necessity for new
molecular markers that define a specific stage of progression for the selection of the
appropriate therapeutic approach independently of tumor stage. This work represents a
whole new era of prostate cancer screening and management, taking in consideration a
panel of biomarkers including, genetic background, protein expression at the molecular
level to predict prognosis and therapy selection as well as the targeting of the
communication network between biological components and the active tumor
microenvironment. All of this valuable information will supplement the use of PSA and
Gleason Scoring and will lead to a better understanding of prostate cancer that will be
used to attain sufficient degree of certainty that would guide the best clinical decisions
based on individual patients.

117

Future Directions
In order to understand the role of cofilin in normal prostate epithelial cells, a mutant
S3ACFL, benign prostate hyperplasia (BPH) cells line will be generated via stable
transfections and migration, invasion and cell adhesion ability will be compared between
wild type and mutant cofilin BPH cell lines.
To examine if TGF-β signaling is required for the suppression of prostate cancer
metastasis on mutant S3ACFL and WTCFL PC-3 cells at the physiological level, the
double transgenic DNTβRII/TRAMP mouse model bearing a dysfunctional TGF-β type 2
receptor will be injected with wild type and mutant cofilin PC-3 cells via tail vein and
metastatic lesions to the lung will be analyzed. This study will allow to characterize the in
vivo consequences of an inactivated TGF-β signaling on mutant S3ACFLand WTCFL
PC-3 cells progression to metastasis. The results will show if a dysfunctional TGF-β
signaling mechanism results in loss of the inhibitory effects of TGF-β leading to an
increase of prostate cancer epithelial cell metastatic potential.
As a secondary model of tumor metastasis, we will use an orthotopic implantation
model of human prostate cancer with the purpose of mimicking closer some of the
characteristics of human cancer metastasis. This model consist on the direct implantation
of PC-3 cells into the ventral lobe of the prostate of athymic mice allowing tumors to
progress for 4 to 6 weeks. At experiment termination, several distinct endpoints will be
measured, such as size and molecular characterization of the primary tumor in terms of
total and phosphorylated cofilin expression, the presence and quantification of circulating
tumor cells in the blood and bone marrow, and number of metastatic lesions to the lung.
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To further investigate the role of cell surface plasma membrane proteins in the process
of prostate cancer metastasis, we are also interested in the development of a double
transgenic TRAMP/EMMPRIN knockout mice, to elucidate the effect of loss of the cell
surface protein EMMPRIN in prostate cancer progression to metastasis.
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APPENDIX

LIST OF ABBREVIATIONS

AR- androgen receptor
ATP- adenosine triphosphate
BPH- benign prostate hyperplasia
CDKs- cyclin dependent kinases
CFL- Cofilin
CRPC- Castration resistant prostate cancer
DAB- Diaminobenzidine
CAFs- Cancer Associated Fibroblasts
CFL- Cofilin
DNA- Deoxyribonucleic Acid
DNTGFRII- Dominant negative Transforming Growth Factor Beta Type II Receptor
EMMPRIN- Extracellular Matrix Metalloproteinase Inducer
ECM- Extracellular Matrix
EDTA- Ethylenediaminetetraacetic acid
EGFR- Epidermal growthfactor receptor
EMT - Epithelial to Mesenchimal Transition
ECM - Extracellular Matrix
EDTA - Ethylenediaminetetraacetic acid
FGF- Fibroblast growth factor
GFP- Green Fluorescent Protein
LIMK- Lim domain kinase
MAPK- Mitogen- activated protein kinase
MTT- (3-(4,4,5-Dimethylthiazol-2-yl)-2,5)-diphenytertazolium bromide
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PCR- Polymerase Chain Reaction
PBS- Phosphate Buffered Saline
PI3K- Phosphatidylinositide 3-kinases
PMSF- Phenylmethanesulfonylfluoride
PSA- Prosta Specific Antigen
PTEN - Phosphatase and tensin homolog
RANKL- Receptor activator of nuclear factor kappa-B ligand
RIPA- Radioimmunoprecipitation Assay Buffer
ROCK1- Rho-associated, coiled-coil containing protein kinase 1
SDS- PAGE - Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SHH- Slingshot phosphatase
TGF-β- Transforming growth factor beta
TMPRSS2- Transmembrane protease, Serine 2
TRAMP- Transgenic adenocarcinoma of the mouse prostate
UGM- Urogenital sinus mesenchyme
UGS- Urogenital sinus
VEGF- vascular endothelial growth factor
VEGF- vascular endothelial growth factor receptor
WT- wild type
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2013

Presented Lecture: (lecture presented to senior high school students). Pursuing a Career in Cancer
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Podium Presentation: Cofilin, A novel regulator of Prostate Cancer Metastasis. First
International Conference in Anticancer Research, Fourth International Conference on Recent
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Chelation, Azzia Resort and Spa Paphos, Cyprus .
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